

Exosomes and other extracellular vesicles in host–pathogen interactions

Jeffrey S Schorey^{*}, Yong Cheng, Prachi P Singh & Victoria L Smith

Abstract

An effective immune response requires the engagement of host receptors by pathogen-derived molecules and the stimulation of an appropriate cellular response. Therefore, a crucial factor in our ability to control an infection is the accessibility of our immune cells to the foreign material. Exosomes—which are extracellular vesicles that function in intercellular communication—may play a key role in the dissemination of pathogen- as well as host-derived molecules during infection. In this review, we highlight the composition and function of exosomes and other extracellular vesicles produced during viral, parasitic, fungal and bacterial infections and describe how these vesicles could function to either promote or inhibit host immunity.

Keywords exosomes; extracellular vesicles; immunity; pathogens

DOI 10.15252/embr.201439363 | Received 25 July 2014 | Revised 6 November 2014 | Accepted 17 November 2014 | Published online 8 December 2014

EMBO Reports (2015) 16: 24–43

See the Glossary for abbreviations used in this article.

Introduction

The ability of the immune system to recognize and respond to pathogenic organisms is essential for the body's ability to control an infection. Divided into the innate and acquired branches, immune responses elicit protection against most pathogenic invaders. A number of mechanisms for how the immune system accomplishes this protection have been defined. Cytokines and chemokines, as well as other inflammatory mediators produced by infected or resident immune cells, clearly recruit and activate leukocytes and other cells, culminating in the elimination of the invading organism. Pathogen-derived products are major drivers of both the innate and acquired immune response. The microbial components that trigger the innate immune response do so either directly by inducing the production of immune effector molecules like reactive oxygen species or indirectly through stimulating the production of cytokines and chemokines. These microbial components that promote the innate immune response are generally defined as PAMPs (pathogen-associated molecular patterns). PAMPs are structurally diverse molecules found across many species of non-pathogenic and

pathogenic organisms and include lipids, proteins, carbohydrates and genetic material. Pattern recognition receptors (PRRs), such as TLRs, present on leukocytes and various non-immune cells, can bind to PAMPs, thereby initiating cell-signaling cascades. This ultimately leads to the activation of an immune response against the pathogen. The importance of PRRs in the recognition and response to pathogens has been shown in both animal infection models and human studies [1]. Given their role in immunity, it is not surprising that pathogenic organisms have evolved methods to modulate the binding and/or signaling through the PRRs as mechanisms to promote their virulence and evade surveillance by the immune system [2,3].

The mechanisms for exposure of PAMPs to PRRs differ between intracellular and extracellular pathogens. For extracellular pathogens, PAMPs are released through an active process or through shedding or death of the organism. The released factors can then directly bind PRRs on immune cells, stimulating or inhibiting host responses. In contrast, intracellular pathogens, such as *Mycobacteria*, *Salmonella* and *Toxoplasma*, produce PAMPs which—like the pathogens they are derived from—have limited exposure to the immune system. Nevertheless, the host does respond to these PAMPs, likely through multiple mechanisms. An obvious source of interaction is the cell invasion process [4–6]. Moreover, a pathogen may be present in the extracellular milieu between host cell entries, allowing for release of PAMPs. This is likely a particularly important mechanism for viral proteins and viral RNA/DNA. The ability of HIV to invade host cells is known to be heterogeneous depending on the interactions with its cellular receptors; a slower invasion leads to increased phagocytosis of the virion by phagocytic cells [7]. However, some intracellular pathogens like *Listeria monocytogenes* can go from cell to cell without being exposed to the extracellular environment [8]. Debris from necrotic infected cells or release of apoptotic bodies from infected cells can also disseminate pathogenic components to surrounding cells/tissue [9]. However, what has become increasingly clear is that exosomes and other extracellular vesicles released from infected cells, as well as from the pathogens, likely play an important role in this dissemination process [10–12]. These components not only include PAMPs, but also T- and B-cell antigens, as well as pathogen-derived toxins.

In this review, we briefly introduce exosomes and how they are generated, as well as their role in non-infectious diseases, with an emphasis on their immune modulatory activity. We then focus in-depth on the production and activity of exosomes and other

Glossary

APC	antigen-presenting cell	LFA-1	lymphocyte function-associated antigen 1
APOBEC3G	apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G	LMP1	latent membrane protein 1
BALF	bronchoalveolar lavage fluid	LPS	lipopolysaccharide
BAT3	HLA-B-associated transcript 3	M.tb	<i>Mycobacterium tuberculosis</i>
BCG	bacillus Calmette–Guérin	MAP kinase	mitogen-activated protein kinase
BMDCs	bone marrow-derived dendritic cells	MC/9	<i>Mus musculus</i> mast cell line
CCR5	C-C chemokine receptor type 5	MCP-1	monocyte chemotactic protein 1
CD	cluster of differentiation	mDC	mature DC
CFP	culture filtrate protein	MFG-E8	milk fat globule-EGF factor 8 protein
CIA	collagen-induced arthritis	MHC	major histocompatibility complex
CMV	cytomegalovirus	miRNA	microRNA
CTL	cytotoxic T lymphocyte	MVB	multivesicular bodies
CXCR4	C-X-C chemokine receptor type 4	MyD88	myeloid differentiation primary response gene (88)
DC	dendritic cell	NF-κB	nuclear factor kappa-light-chain-enhancer of activated B cells
DT	diphtheria toxin	NK	natural killer
DTH	delayed-type hypersensitivity	NLRP3	NACHT, LRR and PYD domains-containing protein 3
EBA-175	erythrocyte binding antigen 175	NPC	nasopharyngeal carcinoma
EBV	Epstein–Barr virus	PAMP	pathogen-associated molecular pattern
EM	electron microscopy	PBMC	peripheral blood mononucleated cells
ESCRT	endosomal sorting complexes required for transport	PIM	phosphatidylinositol mannoside
FACS	fluorescence-activated cell sorting	PRR	pattern recognition receptor
Fas/FasL	Fas and Fas ligand	RANTES	regulated on activation, normal T cell expressed and secreted
HCV	hepatitis C virus	RBC	red blood cell
HEK	human embryonic kidney	RILP	rab-interacting lysosomal protein
HIV	human immunodeficiency virus	RNP	ribonucleoprotein
HLA-DR	major histocompatibility complex, class II, DR beta 1	ROS	reactive oxygen species
HMC-1	human mast cell line-1	SNARE	SNAP (soluble NSF attachment protein) REceptor
HSP	heat-shock protein	TAR	trans-activation response
HSV	herpes simplex virus	TB	tuberculosis
ICAM1	intercellular adhesion molecule 1	TCR	T-cell receptor
iDC	immature DC	TF	tissue factor
IFN	interferon	Tim4	T-cell immunoglobulin mucin protein 4
IL	interleukin	TLR	toll-like receptor
ILVs	intraluminal vesicles	TNF	tumor necrosis factor
JNK	c-Jun N-terminal kinase	VAMP7	vesicle-associated membrane protein 7
LAM	lipoarabinomannan	WT	wild-type
LBPA	lysobisphosphatidic acid		

extracellular vesicles during infection, and how these vesicles could benefit the host immune response but also be used to promote pathogen survival. Finally, we discuss their therapeutic potential, including their use as vaccines and diagnostic tools.

Extracellular vesicles

Extracellular vesicles are broadly defined as membrane-bound vesicles released from cells. Those produced during an infection can be pathogen or host derived. The former include, for example, outer membrane vesicles from gram-negative bacteria and membrane vesicles from gram-positive bacteria. The content and function of these bacteria-generated vesicles has recently been under intensive investigation and excellently reviewed elsewhere [13–15]. Although these vesicles likely play an important role during the course of an extracellular bacterial infection, their role in intracellular pathogen infections is less clear, as mechanisms to transport the vesicles outside the host cell are not known. Parasitic and fungal pathogens also release extracellular vesicles, which may function in modulating the immune response [16,17].

Host-derived vesicles are present during viral, bacterial, parasitic and fungal infections. These vesicles have different origins and composition and, based on their biogenesis, are divided into three main categories: apoptotic bodies, exosomes and microvesicles. All three of these cell-derived vesicles are enclosed by a lipid bilayer, but vary in size (from 30 to 2,000 nm in diameter), as well as in composition. In contrast to microvesicles, which are generated by budding from the plasma membrane [18], exosomes are derived from the endolysosomal pathway and have a unique lipid and protein makeup. Exosomes have been the most studied in the context of infection. An important note, however, is that exosome purity was not always analyzed in these studies, and therefore, the vesicle population may have consisted of both exosomes and microvesicles, which overlap in size and density. Nevertheless, we will use the terminology as defined in the original studies when discussing the results.

Exosomes

Exosomes are formed through the fusion of multivesicular bodies (MVBs) with the plasma membrane and subsequent release of




Figure 1. Exosome biogenesis.

Lipids, proteins and nucleic acids are transported to MVBs and onto or into the intraluminal vesicles, which upon fusion of the MVB with the plasma membrane are released as exosomes. Originally identified as a way to release transferrin receptor from maturing reticulocytes, other plasma membrane proteins have been shown to be targeted to MVBs through various mechanisms and released on exosomes. RNA and cytoplasmic proteins are also transported to MVBs, although the mechanisms mediating this transport are less understood (indicated by dashed line). See Glossary for definitions.

intraluminal vesicles (ILVs) as exosomes (Fig 1). Exosomes are 30–100 nm vesicles, surrounded by a lipid bilayer, that have a density of 1.13–1.19 g/ml. Biophysically, exosomes are equivalent to cytoplasm enclosed in a lipid bilayer with the external domains of transmembrane proteins exposed to the extracellular environment. EM studies have demonstrated the fusion of the limiting membrane of MVB with the plasma membrane, as well as the release of ILVs, in different cell types of hematopoietic origin, such as Epstein–Barr virus (EBV)-transformed B cells [19], mastocytes [20], DCs [21,22], platelets [23], macrophages [10] and cells of non-hematopoietic origin such as neurons and epithelial cells [24–26]. Exosomes can act locally or circulate through various bodily fluids, including blood and lymph, resulting in a systemic response [27]. Exosomes were first identified in the culture media of reticulocytes [28,29]. However, over the past two decades, the study of exosomes has extended to most cell types, and they have been isolated from different organisms—including unicellular eukaryotes—suggesting that this is an evolutionarily conserved mechanism of cell–cell communication. The advantage of using exosomes for cell–cell communication stems from their complex composition, which allows more control over the communication process. Moreover, the presence of signaling lipids, proteins and various species of RNA within a single structure can lead to rapid and profound changes in the target cell, enabling a swift response to cellular perturbations, which can be local or systemic. These changes may be induced under physiological or pathological conditions. Although the complexity of exosomes has clear benefits to the organisms that produce them, it has made the study of their function exceedingly difficult, as the effect of an exosome or pool of exosomes is a result of all the different components within them, including lipids, proteins, carbohydrates and RNA. Moreover, the tools available to modulate exosome production and composition

in vitro and *in vivo* are severely limited, hampering our ability to define exosome function in normal and diseased states. Nevertheless, we have gained important insights into exosome biogenesis, composition and function over the past decade, a decade that has seen a rapid expansion in publications on this type of extracellular vesicle.

Exosome biogenesis

A major mechanism for down-regulating and degrading plasma membrane receptors is through their endocytosis and trafficking to an MVB, which can subsequently fuse with the lysosome to mediate protein degradation [30]. However, at least a subpopulation of MVBs can also fuse with the plasma membrane, resulting in the release of the intraluminal vesicles (ILV) as exosomes. Despite their discovery nearly three decades ago, the mechanism for MVB biogenesis and exosome release is still being defined. Several models have been suggested as a mechanism for ILV formation. Initial studies in yeast demonstrated a role for the ESCRT proteins [31]. Although the ESCRT machinery has primarily been studied for its role in the endosomal sorting and degradation of ubiquitinated proteins, it has also been implicated in mediating membrane invagination [32,33]. Through its ubiquitin-interacting domains, ESCRT-0 clusters ubiquitinated proteins for delivery into MVBs [34]. ESCRT-0 subsequently recruits ESCRT-1 to the endosomal membrane, which in turn recruits the remaining members of the ESCRT machinery, ESCRT-II and ESCRT-III [35,36]. Through the formation of polymeric filaments mediated by ESCRT-III, membrane invagination results in ILV formation [37] (for a recent review, see [38]). Indeed, various studies support a role for the ESCRT machinery in exosome formation. Proteomic analysis of exosomes has demonstrated the presence of ESCRT machinery within exosomes, and knockdown of key components of ESCRT machinery can abrogate ILV formation and exosome release [39], although this is likely cell type-specific [40,41]. While this general model for MVB biogenesis has been well characterized, it is unclear whether this constitutes the major mechanism of MVB formation. A number of studies suggest there are ESCRT-independent mechanisms for MVB biogenesis and exosome release. In oligodendroglial cell lines, exosome formation is driven by the production of ceramide, rather than the ESCRT machinery [41]. Stuffers and colleagues found that depleting specific subunits from the four ESCRTs complexes did not completely inhibit MVB formation [40]. Furthermore, a mechanism independent of both ESCRTs and ceramide has been proposed. Studies by van Niel and colleagues found that the tetraspanin CD63, which is present on exosomes in high abundance, mediates cargo sorting and ILV formation [42]. Additionally, CD81 has been demonstrated to mediate cargo sorting of tetraspanin ligands, such as Rac GTPase, although knockdown of this tetraspanin does not appear to alter MVB morphology or exosome secretion [43]. These different observations suggest that the mechanism for exosome biogenesis and protein sorting may be cell type-specific or specific to different subpopulations of MVBs within a cell. In support of the latter, Stoorvogel and colleagues have shown that within immature DCs, the MHC molecules are targeted to MVBs that are low in cholesterol but enriched for lysobisphosphatidic acid, which are destined for lysosomal degradation. However, in mature DCs, MHC molecules are sorted into MVBs that are enriched in CD9 and cholesterol, which are targeted for fusion with the plasma membrane [44].

Once MVBs are formed, their fusion with the plasma membrane is mediated by the cytoskeleton, fusion machinery—such as the

SNARE proteins—and molecular switches (such as small molecular weight GTPases) [45]. Rab GTPases are members of the Ras GTPase superfamily and are known to regulate four steps in membrane trafficking: vesicle formation, trafficking, tethering and fusion with target organelles. Almost 70 different Rab GTPases have been identified to date in mammalian cells [46]. Several of these have been found on exosomes, including Rab5, Rab11, Rab27 and Rab35. Some of these Rab effectors have been experimentally shown to function in exosome release. Early studies suggested that Rab11 might function to promote MVB fusion with the plasma membrane in the K562 erythroleukemic cell line [47]. More recent studies have implicated Rab35 in mediating MVB docking to the plasma membrane in neuralgia cells, where depletion of Rab35 resulted in a significant loss in exosome release [48]. Rab27a and Rab27b were also shown to have different, but sometimes redundant, roles in MVB biogenesis, with Rab27a more implicated in mediating MVB docking to the plasma membrane [49]. Although the Rab GTPases have been implicated in MVB trafficking and fusion, their role in the process is still under investigation and will likely be cell type-dependent, as well as dependent on the physiological/pathological state of the cell.

Exosome composition

Exosomes contain all types of biomolecules, including proteins, carbohydrates, lipids and nucleic acids. Their lipid and protein composition has been extensively analyzed by various techniques, including Western blotting, FACS, immuno-EM and mass spectrometry. Exosome composition will vary depending on the cell type of origin, its physiological/pathological state and even the cell site of origin, as seen in epithelial cells. Epithelial exosomes have different composition if they are released from the apical or basolateral surfaces [50]. Cell type-specific markers can help define the exosome cellular origin; for example, the presence of T-cell or B-cell receptors is indicative of T-cell and B-cell origin, respectively. The exosome protein composition can also be informative of the existence of a pathology, as they can, for example, carry tumor antigens or inflammatory mediators. In addition, exosomes contain a number of common proteins, including Tsg101, Hsc70 and various tetraspansins [51], as well as proteins that participate in vesicle formation and trafficking, such as the LBPA-binding protein, Alix [52]. Exosome lipid composition has also been well characterized. As for proteins, the ratios of the different lipids can vary between exosomes released from different cellular origins. In general, exosomes are enriched in lipids such as sphingomyelin, phosphatidylserine, gangliosides and cholesterol, as compared to plasma membranes and other intracellular membranes [53]. A number of reviews have highlighted the protein and lipid content of exosomes [54,55], and various databases have cataloged the protein, lipid and RNA content of exosomes (ExoCarta, <http://www.exocarta.org/>, Vesiclepedia, <http://microvesicles.org/>).

Most recent studies have focused on exosomal RNA; the types of RNA and their nucleotide sequence, their ability to be transferred between cells, their function once transferred and the mechanism by which they are trafficked to MVBs and into exosomes. Pioneering studies by Valadi and colleagues showed that exosomes are enriched in mRNA and miRNA [56]. More recent studies have identified other non-coding RNAs in exosomes, but limited amounts of DNA or ribosomal RNA [57]. The exosomes derived from a human (HMC-1) and mouse (MC/9) mast cell lines were found to

transport mRNA to neighboring mast cells. This mRNA was subsequently translated, indicating that it is biologically active [56]. Exosomes released by immune cells have been shown to contain a selective repertoire of miRNAs that can be functionally transferred to recipient cells [58,59]. The source of these exosomes/extracellular vesicles were cultured cells [60] and body fluids [61,62]. Together, these data suggest that exosomes function as carriers of genetic information and that this genetic material plays a role in cell–cell communication. However, the exosomal RNA content differs both in quantity and in composition depending of the cellular origin and cellular environment. Eldh and colleagues found that the exosomes released by mast cells differ in their mRNA content after exposure to an oxidative stress, and oxidative stress resistance was induced in recipient cells [63]. These results indicate that the incorporation of RNA into vesicles is a regulated event leading to selective packaging of RNA into exosomes and other extracellular vesicles [64,65]. The mechanism(s) responsible for the targeted loading of RNA into exosomes is still being defined and remains an active area of investigation.

In addition to host components, a number of pathogen-derived components have been found on exosomes after cell or animal infection (Table 1). Unfortunately, we know very little about how these diverse pathogen-derived proteins, glycolipids, etc. are sorted to MVBs and onto exosomes (see Sidebar A). Much of our current understanding stems from studies of viruses, where viral assembly and exosome biogenesis share many similarities. For example, HIV assembly and release from infected cells depend on both ESCRT machinery and tetraspanin-rich lipid domains [66,67]. The presence of viral proteins in exosomes and the similarities in biogenesis and assembly suggest that a degree of ‘crosstalk’ or ‘hijacking’ could be responsible for sorting the viral proteins into exosomes. However, some viral proteins—such as the HIV protein Nef—may contain necessary signals to mediate their direct sorting into exosomes [68]. For other types of pathogens, even less is understood. Some intracellular bacterial pathogens, such as *Mycobacterium tuberculosis*, are also known to interfere with host machinery implicated in exosome biogenesis, such as ESCRTs [69], although the extent to which this contributes to protein sorting during exosome biogenesis is unclear. Based on our observations, sorting of mycobacterial proteins seems to be independent of cell entry mechanisms, as mycobacterial proteins are found on exosomes whether added as free protein, and therefore taken in through an endocytic route, or expressed in mycobacteria, which enters by phagocytosis [11]. This finding suggests that these mycobacterial proteins have the necessary ‘signal’ to be trafficked to the MVB during exosome biogenesis. However, further investigation is needed to shed light on potential sorting mechanisms.

Viral RNAs have also been found within exosomes. HCV viral RNA transport to exosomes was found to be dependent on the ESCRT machinery and on Annexin A2, an RNA-binding protein involved in membrane vesicle trafficking [70]. Similarly, EAP30—a subunit of ESCRT-II—controls HIV-1 RNA trafficking and gene expression through a complex formed by HIV-1 Gag, ESCRT-II and Staufen-1 [71]. The mechanism by which EAP30/ESCRT-II facilitates HIV-1 genomic RNA trafficking remains unclear, although—considering the roles for ESCRT-II in the nucleus [72]—EAP30/ESCRT-II is likely part of the RNP complex that mediates the nuclear export of viral RNA. Other partners of EAP30, such as EAP45, have an RNA-binding domain that is likely conserved [73,74], and RILP

Table 1. Pathogen components present on exosomes/extracellular vesicles released from infected cells.

Pathogen	Vesicle contents	References
HIV	Gag proteins	119
	Nef protein	68,121,123,124
	TAR transcripts	120
EBV	Viral RNAs	134
	LMP1	129
	LMP2a	130
CMV	Glycoprotein B	138
Hepatitis C virus	Viral RNAs	70
	Viral RNA/proteins	141,142
	Envelope glycoprotein E2	139
HSV	Viral tegument proteins and various glycoproteins	146
<i>Toxoplasma gondii</i>	PAMPs	10
<i>Leishmania mexicana</i>	GP63	156
	Proteomic analysis	156
<i>Leishmania major</i>	GP63	157
<i>Leishmania donovani</i>	GP63	158
	Proteomic analysis	155
	Proteomic analysis	160
<i>Plasmodium falciparum</i>	EBA-175, EBA-181	162
	Proteomic analysis	162
	PfPTP2	163
<i>Mycobacterium tuberculosis</i>	LAM, PIM	10,180,181
	19 kDa lipoprotein	10
	Proteomic analysis	11
	mRNA	J.S. Schorey, unpublished data
<i>Mycobacterium avium</i>	GPLs	182
<i>Salmonella typhimurium</i>	LPS	10
<i>Mycoplasma</i>	Lethal factor	195
	Proteomic analysis	195

—which associates with EAP30—can also have an effect on the localization of viral RNA in the cytoplasm. EAP30/ESCRT-II could also contribute to the stability of cellular factors that are required for viral RNA trafficking.

Exosomes as modulators of the immune response

Most studies of exosomes and their effect on the immune response are in the context of cancer and autoimmunity. These studies have: (i) defined the host molecules that facilitate exosome transfer; (ii) characterized the presence of tumor antigens on exosomes and

mechanisms by which these antigens can promote T-cell activation; (iii) defined the mechanisms by which some exosomes can induce T-cell anergy and deletion; and (iv) defined the RNA content within the exosomes, as well as characterized their transcriptional and translational effect on recipient cells [75]. Other studies have characterized exosomes as drivers of an innate immune response, although significantly less work has been done in this area [76].

Innate immunity

Dendritic cells produce exosomes constitutively and have been implicated in the activation of the innate immune response (Fig 2). Exosomes from both immature and mature DCs contain multiple TNF superfamily members—such as TNF, FasL and Trail—on their surface, which directly bind to the surface receptors on NK cells to enhance their cytotoxic activity. However, the activation of NK cells is significantly stronger in response to exosomes released from activated DCs [77]. Similarly, exosomes from DCs express BAT3 (HLA-B-associated transcript-3) and thus are recognized by the NK surface receptor, NKp30, leading to NK-cell activation [78]. DCs activated by lipopolysaccharide (LPS) release extracellular vesicles that can stimulate epithelial cells to secrete chemokines—such as IL-8 and RANTES—which may be an important component in the pathogenesis of sepsis [79]. DC-derived microvesicles have also been shown to induce NF- κ B activation in microglia cells, which may play a role in the inflammatory response observed in the CNS during experimental autoimmune encephalomyelitis (EAE) [80]. IL-1 β , a major driver of the innate immune response, is produced as a pro-form and converted to its active form through cleavage by the inflammasome. The mature form is released by activated macrophages and DCs through a non-classical secretion pathway. Qu and colleagues propose that trafficking via exosomes may be one mechanism for IL-1 β release, although this was not definitively proven because exosomes containing the mature IL-1 β could not be isolated after ATP stimulation of bone marrow-derived macrophages [81,82]. In the presence of oxidized low-density lipoprotein (oxLDL)-conjugated immune complexes, macrophages release exosomes containing IL-1 β , as well as increased levels of acid sphingomyelinase and HSP70, and these exosomes may promote the propagation of atherosclerotic plaques [83]. These and other studies clearly demonstrate a role for exosomes/extracellular vesicles in regulating inflammatory and innate immune responses. As described below, their role is likely more pronounced in the context of an infection, as these exosomes could carry both host and pathogen components.

Acquired immunity

The presence of MHC class I and II, as well as T-cell co-stimulatory molecules, on the surface of macrophage- and DC-derived exosomes has attracted the interest of immunologists, as exosomes may be an important mechanism of antigen presentation. Since exosomes can carry foreign antigens in the context of an infection, defining the mechanisms by which this antigen presentation occurs is important to understanding the immune response to the pathogen. There are currently three proposed models for exosome-mediated antigen delivery to T cells (Fig 2).

1) *Cross-dressing pattern*. In this model, DCs capture extracellular exosomes and directly present antigenic peptide–MHC complex to CD4⁺ or CD8⁺ T cells, suggesting that exosomes shuttle peptide–MHC II complex between DC populations [84–87].




Figure 2. DC-derived exosomes modulate innate and acquired immune responses.

Exosomes from mature DCs (mDCs) can provide antigen to T cells, stimulate innate immune responses in various immune and non-immune cells and promote a pro-inflammatory response. This is mediated by host factors present within the exosomes, such as those indicated in the figure. In contrast, exosomes from immature DCs (iDCs) seem to be immuno-suppressive, and induce apoptosis in effector T cells or promote the activation of regulatory T cells. CIA, collagen-induced arthritis; DTH, delayed-type hypersensitivity. See Glossary for definitions.

2) *Cross-presentation pattern*. In this scenario, bystander DCs capture the exosomes containing the proteins/peptides and then present these exosome-delivered antigens on their endogenous MHC class I and II molecules for subsequent activation of antigen-specific T cells [88,89]. Both of these mechanisms require the capture of exosomes by recipient cells, and thus the receptors and ligands that facilitate this interaction have been the object of study. Several exosome surface ligands and adhesion molecules have been identified, including MFG-E8/lactadherin, tetraspanins, ICAM1 and phosphatidylserine [22,90,91]. MFG-E8 binds to the integrins $\alpha v \beta 3$ and $\alpha v \beta 5$, which are constitutively expressed by human DCs and macrophages, but also recognizes phosphatidylserine on the cell surface through its phosphatidylserine-binding domain [22,90]. Exosomal phosphatidylserine may also interact with DC surface protein Tim4 [92,93]. The uptake of DC-derived exosomes is not limited to bystander DCs, as exosomes can transfer peptide–MHC I complex and co-stimulatory molecule CD80 to non-specific CD4⁺ T cells, which then acquire the capacity to activate antigen-specific/naïve CD8⁺ CTLs *in vivo* and *in vitro* [94]. Furthermore, upon the formation of an immunological synapse between mature DCs and T lymphocytes, exosomes released from DCs specifically bind to activated T cells

in a LFA-1-dependent manner and could potentiate T-cell activation [95].

3) *Direct exosome-induced T-cell activation*. Since DC-derived exosomes contain MHC class I and II, as well as co-stimulatory molecules, they have the potential to directly activate CD4⁺ or CD8⁺ T cells [87,96–98]. Although this mechanism has mostly been observed for memory or previously activated T cells [99,100], some studies have shown exosome-mediated activation of naïve T cells. Using transfected *Drosophila* APCs and mouse CD8⁺ T cells, Hwang and colleagues demonstrated that APC-derived extracellular vesicles directly activate naïve CD8⁺ T cells *in vitro* [101]. This activation requires the presence of ICAM1 on the vesicles, which likely functions to promote adhesion between the exosomes and T cells. The presence of the co-stimulatory molecule B7 on the vesicles was also necessary. Direct stimulation of naïve PBMC-derived CD8⁺ T cells was also detected in the presence of viral MHC I-specific peptide-loaded exosomes [91]. Although direct activation of naïve T cells has been observed, studies suggest that T-cell stimulatory activity by vesicles alone is 10- to 20-fold less efficient than when presented by an APC [19,102], suggesting that direct exosome–T-cell interaction may not be a major mechanism of naïve T-cell activation *in vivo*. Nevertheless, both *in vitro* and *in vivo* data suggest that

DC-derived exosomes likely function in antigen presentation to T cells. This ability to stimulate T cells may depend on the activation state of the DC, as exosomes from activated DCs have more MHC class II, ICAM1 and costimulatory molecules than exosomes from immature DCs [91]. Unfortunately, we do not yet have the tools to specifically block exosome-mediated antigen presentation *in vivo* and, therefore, the contribution of the exosome to T-cell activation in animal models is still unclear.

In contrast to exosomes from mature DCs, those derived from immature DCs have been shown to promote T-cell anergy/deletion as well as to promote the activation of regulatory T (Treg) cells. Thus, exosomes have been evaluated for the potential treatment of autoimmune diseases (Fig 2), a topic that has recently been the subject of several excellent reviews [75,103,104]. Exosomes are also released from lymphocytes, such as CD4⁺ and CD8⁺ T cells, which constitutively secrete exosomes containing the TCR/CD3 complex. However, the production of these exosomes increases when they are activated through TCR ligand binding [105]. The function of these exosomes will depend on the activation status and tissue microenvironment of the T cell and can broadly be classified into two main categories based on their immunological functions, either activating or suppressive.

1) *Immuno-activation*. Exosomes from activated T cells may potentiate an immune response through effects on resting autologous T cells. For example, when activated with anti-CD3 and IL-2, human peripheral CD3⁺ T cells release exosomes that stimulate cytokine secretion and proliferation of CD8⁺ T cells *in vitro* [106].

2) *Immuno-suppression*. CD4⁺CD25⁺FOXP3⁺ Treg cells release exosomes containing CD73, an ecto-5'-nucleotidase enzyme that converts extracellular adenosine-5-monophosphate to adenosine, which is an anti-inflammatory mediator, thereby inhibiting CD4⁺ T-cell proliferation [107]. Exosomes from activated effector CD4⁺ T cells can interact with DCs through specific peptide–MHC I/TCR and CD54/LFA-1 interactions and inhibit the ability of the recipient DCs to stimulate CD4⁺ T-cell proliferation, as well as inhibit an *in vivo* CD8⁺ CTL response [108]. Moreover, CD8⁺CD25⁺ Tregs release exosomes that could inhibit a CD8⁺ T-cell antitumor response [109]. Exosomes released from CD4⁺ T cells containing FasL induce apoptosis in recipient T cells [110,111]. Further, human B-cell-derived lymphoblastoid cell lines (LCL) constitutively produce FasL-positive exosomes that can induce apoptosis in CD4⁺ T cells [112].

The balance between exosomes that promote T- and B-cell activation and those that inhibit lymphocyte function is thought to be an important component in the pathogenesis of many diseases including cancers, cardiovascular diseases and autoimmune diseases. As reviewed below, during an infection, exosomes also function in immune modulation, including activation and inhibition of T cells, which likely has an important role in disease pathogenesis.

Exosomes and other extracellular vesicles in infectious disease

Exosomes and other extracellular vesicles, both pathogen- and host-derived, have been isolated and characterized in all known pathogen classes, including viruses, bacteria, fungi and parasites (Table 2). As one would expect, the composition and activity of these exosomes

Table 2. Exosome production by host cells upon infection.

Pathogen	Host resources	References
Viruses		
Human immunodeficiency virus (HIV)	DCs, T cells	68,71,119–121, 124,127
Epstein–Barr virus (EBV)	B cells	129–131,133–135
Cytomegalovirus (CMV)	Endothelial cells	137,138
Herpes simplex virus (HSV)	Melanoma cells	144–146
Hepatitis C virus (HCV)	Hepatocytes, Serum	70,139–142
Bacteria		
<i>Chlamydia trachomatis</i>	Fibroblast	198
<i>Chlamydia pneumoniae</i>	ECV304 cells	197
<i>Mycobacterium tuberculosis</i>	Macrophages, Plasma	10,11,180,181,186, 187,190,191
<i>Mycobacterium bovis</i> BCG	Macrophages, Plasma, BALF	186,189
<i>Mycobacterium smegmatis</i>	Macrophages	184
<i>Mycobacterium avium</i>	Macrophages	182–184
<i>Salmonella typhimurium</i>	Macrophages	10
<i>Mycoplasma</i> spp.	Tumor cells	195
<i>Bacillus anthracis</i>	Retinal pigment epithelial cells	196
Protozoa		
<i>Leishmania donovani</i>	Macrophages	156
<i>Plasmodium vivax</i>	Plasma	161
<i>Plasmodium berghei</i>	Plasma	164
<i>Plasmodium falciparum</i>	Erythrocytes	162–164
<i>Plasmodium yoelii</i>	Reticulocyte, Plasma	160
<i>Toxoplasma gondii</i>	Macrophages	10
<i>Trypanosoma cruzi</i>	Macrophages	165
Fungi		
<i>Malassezia sympodialis</i>	DCs, Plasma	176

vary significantly between the different taxa and even between pathogens in the same genus. Other factors such as the animal model used, the experimental design, the cell types chosen for the infection and which recipient cells are targeted can affect the observed immune response. We classify our current knowledge according to pathogen class and use specific examples to illustrate the major points.

Viruses

As mentioned above, a number of studies have recognized commonalities between the assembly and release of viruses and exosomes, and identified key host components that are used in both viral and exosome biogenesis. The readers are referred to recent reviews that have highlighted these interesting studies [113,114]. During the course of a viral infection, host cells release exosomes and other extracellular vesicles carrying viral and host components, which can modulate the immune response.

Exosomes and other extracellular vesicles generated during HIV infection have been extensively studied. Most studies have addressed the origin of viral budding (plasma membrane or exosomes) and the role of host proteins such as the ESCRTs in this process [115,116], although a few have looked at the role of host-derived extracellular vesicles in the pathogenesis of HIV. Exosomes and other extracellular vesicles released from infected PBMC or megakaryocytes and platelets contain CCR5 and CXCR4, respectively. In both cases, the chemokine receptors could be transferred to target cells, enhancing their susceptibility to HIV infection [117,118]. The HIV membrane protein Gag has been found on exosomes from Jurkat T cells, and this transport seems to be dependent on its oligomerization [119]. Pathogen-associated RNAs, including viral TAR RNA, have been detected in exosomes isolated from the supernatants of HIV-1-infected T cells and from patient sera. TAR RNA can down-regulate apoptotic signals, and therefore, recipient cells might support enhanced HIV replication [120]. Additionally, the HIV virulence factor Nef was detected in exosomes released from HIV-infected cells, the function of which has been extensively studied [121]. Mortalin, a member of the HSP70 family, appears to interact specifically with Nef and may play a role in its targeting to MVBs [122]. Work by Campbell and colleagues showed that Nef is present in exosomes secreted from transfected HEK 293 cells, which upon fusion with uninfected Jurkat T cells restores infectivity to Nef (-) HIV virions [121]. Nef-containing exosomes released from transfected SupT1 and Jurkat T cells can induce CD4⁺ T-cell apoptosis *in vitro*, pointing to their possible role in the T-cell depletion inherent to HIV pathogenesis [68]. The effect of Nef may not be limited to T cells, as endothelial cell exposure to Nef results in an increased production of ROS and MCP-1 and increased endothelial cell apoptosis [123]. Nef expression also appears to affect the cellular miRNA content within exosomes, potentially limiting the effects of RNA interference in recipient cells [124]. In contrast to the immune inhibitory effects, exosomes secreted from CD8⁺ T cells suppress HIV-1 transcription within infected cells in a protein-dependent but antigen-independent and MHC-unrestricted manner [125]. Furthermore, host-derived exosomes containing APOBEC3G, a cytidine deaminase that functions in cellular anti-retroviral activity, can inhibit HIV replication in the recipient cells [126]. These results suggest that exosomes and other extracellular vesicles can either promote or inhibit HIV replication, and the balance of these two functions will depend on the cells releasing the vesicles, the target cells and likely many other as yet undefined factors.

Human gamma herpesviruses, such as the Kaposi sarcoma-associated virus and EBV, have complex effects on the immune system, leading not only to viral infection but also, in some cases, to cancer, such as nasopharyngeal carcinoma (NPC). Most research on exosomes from herpesvirus-infected cells has focused on their role in cancer pathogenesis, more than on viral pathogenesis and immune responses [127,128]. Nevertheless, a few key studies have shed light on the immunology of EBV infection in the context of extracellular vesicles. Dukers and colleagues discovered that LMP1, a signal transduction protein important in EBV infection, could block the proliferation of T cells and inhibit NK-cell cytotoxicity [129]. LMP1 is present on exosomes from EBV-infected cells, suggesting that they could be a vehicle for the immunosuppressive effects of LMP1 during EBV infection. LMP2a was also found on

exosomes, but its function within these extracellular vesicles has not been explored [130]. Galectin-9, which is present in exosomes released from EBV-infected cells, induces apoptosis of EBV-specific CD4⁺ T cells through its interaction with the T-cell immunoglobulin mucin-3. This receptor is known to negatively regulate both macrophage and T-cell activation [131]. However, exosomes from EBV-infected cells have also been shown to contain the dUTPase, which can induce NF- κ B activation and cytokine release from primary DCs and PBMC, driving a pro-inflammatory/anti-viral response [132]. In addition, EBV encodes for a surprising number of miRNAs—44 have been currently identified [133,134]. These miRNAs not only modify the transcriptome of the infected cells, but also that of uninfected cells through the transfer of the viral miRNA through exosomes. Pegtel and colleagues demonstrated that EBV-infected B cells release exosomes containing EBV miRNAs that induce miRNA-mediated repression of confirmed EBV target genes, including *CXCL11*, an immunoregulatory gene involved in antiviral activity [135]. The ability of EBV miRNAs to be transferred from infected B cells to non-infected T cells and monocytes suggests that exosomal transport of viral miRNAs could contribute to EBV persistence in humans. This hypothesis is supported by the observation that EBV miRNA present in exosomes can target the miR-223 binding site in the 3'-untranslated region of the NLRP3 inflammasome, inhibiting production of IL-1 β [136].

Exosomes released from CMV-infected human endothelial cells can stimulate memory CD4⁺ T cells isolated from CMV-infected donors, likely through the transfer of antigen to allogenic DCs [137]. In the case of the human CMV, microvesicles released by infected cells contain soluble DC-SIGN, a C-type lectin family molecule, in complex with the CMV glycoprotein B. The transport of this complex through microvesicles increases the susceptibility of recipient cells to CMV [138]. Similarly, in HCV-infected patients, the association of cellular membrane protein CD81 with HCV envelope glycoprotein E2, and the subsequent release of this complex within microvesicles, increases the infectivity of previously naïve recipient cells [139]. HCV structural proteins have been found in exosomes isolated from the sera of HCV-infected patients [139], and exosome-like vesicles have been purified from infected cells [140]. Purified exosomes isolated from HCV-infected human hepatoma cells contain intact viral particles with full-length viral RNA and protein, and these exosomes can transfer infectivity to naïve hepatoma cells, resulting in a productive infection [141,142]. Dreux and colleagues reported that exosomes released from HCV-infected cells can induce IFN- α release from uninfected plasmacytoid DCs due to the viral RNA present within the exosomes [70]. These results suggest that export of viral RNA may serve both as a viral strategy to evade pathogen sensing within infected cells and as a host strategy to induce an innate response in bystander cells. Similar findings were reported by Li and colleagues, who showed that IFN- α -treated liver non-parenchymal cells release exosomes that contain a number of host molecules with antiviral activity, and this activity can be transferred to hepatocytes that were previously permissive to hepatitis B virus infection [143]. HSV may divert transport of HLA-DR to MVBs and exosomes, thus limiting the amount of peptide-MHC complex on the cell surface of the HSV-infected cells, allowing the virus to evade detection by the immune system [144]. HSV also releases exosome-like vesicles, previously known as L particles, which are of




Figure 3. Modulation of host immunity by exosomes during a viral or parasitic infection.

Virus- or parasite-infected cells, or the parasites themselves, release exosomes or microvesicles that can stimulate T-cell activation by providing antigens to APCs. In contrast, exosomes containing microbial molecules, such as HIV Nef or *Leishmania* GP63, can block T-cell activation or induce the apoptosis of immune effector cells. Extracellular vesicles released from virus- or parasite-infected cells can modulate both the innate and acquired immune response. In some cases, this is to the benefit of the pathogen, whereas in others, this is to the benefit of the host. Dashed lines indicate unknown mechanisms. See Glossary for definitions.

similar size to exosomes and originate on an internal membrane, but are not exosomes [145]. These vesicles contain viral tegument proteins and glycoproteins, including transcription factors that can facilitate the replication of other viral particles in recipient cells [146]. The generation of a recombinant Coxsackie virus expressing ‘fluorescence timer’ protein (Timer-CVB3) has recently allowed to detect increased shedding of microvesicles containing virus in partially differentiated infected progenitor cells *in vivo*, suggesting their role in virus dissemination [147].

Extracellular vesicles have thus been implicated in the pathogenesis of many different viruses (Fig 3). Upon release, exosomes and other extracellular vesicles are ‘captured’ by cells and the transfer of host and viral proteins and/or RNA could enhance viral infection

and replication in recipient cells, as observed for HIV and other viruses. Furthermore, as highlighted above, exosomes released from virus-infected cells can inhibit both CD4⁺ and CD8⁺ T-cell activation. Other studies further suggest that infected cell-derived extracellular vesicles can promote the innate and acquired immune response through cytokine production and antigen presentation [143,148]. Additional studies are clearly needed to unravel how and when these extracellular vesicles promote or limit anti-viral immunity.

Parasites

Toxoplasma gondii was the first non-viral pathogen to be studied in the context of exosomes. In studies by Dimier-Poisson and

colleagues, DCs were pulsed with *T. gondii* proteins, and the exosomes released from the DCs could stimulate a protective immune response against acute and chronic *T. gondii* infection when adoptively transferred to mice. This response was antigen specific and included both cellular and humoral immunity [149]. When used as a vaccine, these exosomes were also associated with the development of fewer brain cysts in *T. gondii*-infected CBA/1 mice [150]. Exosomes isolated in a similar manner were shown to be an effective vaccine for preventing congenital toxoplasmosis when given to mice before pregnancy [151]. We found that exosomes released from the human monocytic cell line THP-1 after infection with *T. gondii* could stimulate non-infected THP-1 cells to produce TNF- α and other pro-inflammatory mediators [10], although the exosomal component responsible for this activity remains undefined. *T. gondii* resides within a vacuole with only limited contact with the endocytic network [152], so how the parasite components are transported to the MVB and onto exosomes is unclear. However, *T. gondii* may be in contact with the endosomes, at least transiently, through a microtubule network [153].

Leishmania spp. have also been well studied in the context of exosomes [16]. The initial studies by Reiner and colleagues established that pathogen-derived exosomes are a vehicle for *Leishmania* protein secretion and uptake by target macrophages [154]. Exosomes were proposed to be a mechanism to deliver *Leishmania* molecules directly into macrophages. *Leishmania* exosomes were also found to suppress the immune response and the heat-shock protein 100 (HSP100) to have an important role in the packaging of the parasite's proteins into exosomes, as its absence from exosomes resulted in different cargo and a different (pro-inflammatory) effect on immune cells [155]. A similar effect was seen *in vivo*, as mice treated with *Leishmania major* and *Leishmania donovani*-released exosomes prior to infection had higher parasite load compared to untreated mice, likely due to the suppression of the immune system by the exosomes [155]. Moreover, proteomic analysis of exosomes from *Leishmania mexicana*-infected macrophages identified parasite and host proteins, which differed between exosomes from uninfected and infected cells [156]. GP63—an important *Leishmania* virulence factor—is present in exosomes from infected cells, which can trigger the expression of genes related to the immune system in recipient cells. This includes signaling molecules such as MAP kinases (except JNK) and transcription factors like NF- κ B. However, the overall effect is the down-regulation of pro-inflammatory genes and suppression of macrophage activation, which would promote parasite survival. This suppression may stem, at least in part, from the expression of GP63 within infected macrophages, as cells infected with a WT and GP63-deficient *L. major* released exosomes with significantly different host and microbial protein content, including proteins known to function in immune modulation [156,157]. Moreover, exosomes containing GP63 released from *L. donovani*-infected macrophages target the pre-miRNA processor Dicer1 in hepatocytes to prevent miRNP formation and block production of the miR122, resulting in altered serum cholesterol concentration and higher parasite burden [158]. In contrast, Schnitzer and colleagues showed that DC-derived exosomes containing *Leishmania* antigens, when used as a vaccine, provide protective immunity against cutaneous leishmaniasis [159].

The study of exosomes in the context of a *Plasmodium* infection is relatively new and has focused primarily on host-derived versus

pathogen-produced vesicles. These studies suggest that host exosomes can modulate the host immune response or parasite survival (Table 2). In work by Martin-Jaular and colleagues, exosomes isolated from the blood of *P. yoelii*-infected BALB/c mice were found to contain parasite proteins and, when used as a vaccine in naïve mice, provided protection against subsequent *P. yoelii* infection [160]. These exosomes stimulated the production of IgG antibodies that recognized *P. yoelii*-infected red blood cells (RBC), decreased the level of parasitemia, allowed infected animals to survive longer and resulted in a preferential infection of reticulocytes over other RBC developmental stages. The production of exosomes during a *P. falciparum* infection may be more limited than during infections with the parasites described above, which replicate inside macrophages, as *Plasmodium* primarily infects RBCs, which lack MVBs. However, like *P. vivax* [161], *P. falciparum* can also infect reticulocytes and these infected cells could produce exosomes during a *P. falciparum* infection. In addition, *P. falciparum*-infected RBCs release exosome-like vesicles and microvesicles, which may enhance infectivity, as their number increases during an infection and they contain parasite components, including proteins that promote pathogen invasion of RBCs, such as EBA-175 and EBA-181 [162]. Interestingly, a recent study found exosome-like vesicles carrying the *P. falciparum* protein PfPPT2 released from infected RBCs, which promoted the sexual differentiation of a subset of parasites [163]. Couper and colleagues demonstrated that microvesicles isolated from the plasma of malaria-infected, but not naïve, mice induce potent, TLR4-dependent activation of macrophages *in vitro*, as measured by CD40 up-regulation and TNF- α production [164]. Conversely, host-derived microvesicles released from both *Trypanosoma cruzi*- and *P. falciparum*-infected cells limit host immune surveillance, leading to increased parasite production and transmission [165,166]. These studies suggest that microvesicles released from *Plasmodium*-infected host cells may play a prominent role in modulating the immune response. Most data suggest that they enhance the pro-inflammatory response, thereby linking microvesicles to disease pathology [167]. This conclusion is supported by the timing associated with microvesicle release, which peaks late during schizogony—a few hours prior to parasite egress—and therefore may partly drive the strong cytokine response associated with the 72-h *P. falciparum* infection cycle [166].

Exosomes have also been identified during other parasitic infections, including those by *Eimeria* spp., which are responsible for avian coccidiosis. Del Cacho and colleagues observed that DCs pulsed with *Eimeria* antigens or exosomes released from the antigen-pulsed DCs could be used as a vaccine against *Eimeria* infection in chickens [168]. Infection with the gastrointestinal parasite *Cryptosporidium parvum* was shown to increase exosome release from intestinal and biliary epithelial cells into the lumen of the gastrointestinal tract [169]. These exosomes also carried antimicrobial peptides from the epithelial cells, the export of which was increased through TLR4 activation by the parasite. The antimicrobial exosomes were shown to have a negative effect on the parasites *in vitro* and *ex vivo*, decreasing their ability to survive and infect host cells [169].

The study of exosomes and other extracellular vesicles in the context of a parasitic infection is complicated by the fact that both the pathogen and host make and release vesicles into the extracellular environment and both likely play a role in disease pathogenesis (Fig 3). Despite significant interest in exosomes in the context of

these infections, we have only begun to characterize their role in pathogenesis. Future studies should develop mechanisms to inhibit/modulate both pathogen- and host-derived vesicles.

Fungi

Most of the studies of extracellular vesicles in fungal infections have focused on exosome-like vesicles released directly by the fungi. Casadevall and colleagues demonstrated the export of exosome-like extracellular vesicles from the fungus *Cryptococcus neoformans* and found they could react with sera from patients infected with the fungus, indicating the presence of fungal antigens in/on vesicles [170–173]. As foreign materials, these exosome-like vesicles activate macrophages, leading to increased production of cytokines, such as TNF- α , and other anti-microbial molecules, thereby restricting fungal infection [172]. In contrast, other studies suggest that these vesicles may promote fungal virulence. Panepinto and colleagues showed that interfering with the export of exosomes from *C. neoformans* by knocking down *Sec6* (a gene involved in the fusion of exocytic vesicles with the cell membrane) resulted in decreased virulence of the fungi *in vivo* [174]. Knockdown of *Sec6* completely inhibited extracellular vesicle production in *C. neoformans*, including that of fungal exosomes, and blocked the export of a major virulence factor, laccase. This enzyme is required for the synthesis of melanin, an important molecule for fungal virulence [171]. The importance of melanin in fungal pathogenesis is suggested by the recent observation that fungal cell walls harboring melanin promote fungal infection by blocking macrophage phagocytosis [175]. A number of studies have shown the release of extracellular vesicles from other fungal species, such as *Malassezia sympodialis* and

Paracoccidioides brasiliensis, but they have provided limited insight into the influence of the vesicles in pathogenesis [176–179]. The role of extracellular vesicles in fungi has been comprehensively reviewed recently [17].

Bacteria

Exposure of the immune system to bacterial and other microbial components is key to both control of the pathogen and subversion of the immune system by the pathogen. Many of the bacterial components known to be involved in the activation/subversion of the immune response are secreted or released from the bacteria during an infection. Understanding how these bacterial components disseminate is important to our understanding of the disease and how our immune system responds to the infection. As highlighted above for viral and parasitic infections, exosomes could play a vital role in this dissemination process. Much of our information regarding exosome production and function during a bacterial infection stems from work on mycobacteria, which will be discussed first, followed an analysis of exosomes in other bacteria.

Russell and colleagues observed that *M. tuberculosis* PAMPs, such as LAM and PIM, are transported from the phagosome to the MVB during a macrophage infection. These PAMPs are also found in extracellular vesicles released by infected macrophages, and their content can be detected inside neighboring uninfected cells [180]. These vesicles have markers of a late endosomal/lysosomal compartment and are released through calcium-dependent exocytosis [181], implying they are exosomes.

Our studies have expanded on these original observations (Fig 4). We determined that *Mycobacterium avium*-infected macrophages




Figure 4. Bacteria-infected cells release exosomes that modify T-cell and macrophage function.

Exosomes from bacteria-infected macrophages release exosomes containing antigens that induce cross-priming to activate antigen-specific CD4⁺ and CD8⁺ T cells. In contrast, some exosomes released from infected cells inhibit cytokine production by T cells. Exosomes from infected cells also contain PAMPs that stimulate macrophage production of pro-inflammatory mediators like TNF- α , or limit the macrophage response to IFN- γ stimulation. Dashed lines indicate unknown mechanisms. See Glossary for definitions.

release vesicles that can stimulate a pro-inflammatory response in non-infected or ‘bystander’ macrophages [182]. Similar results were reported by Wang and colleagues [183]. Anand and colleagues observed increased exosome production in macrophages infected with *M. avium* and *M. smegmatis* compared to uninfected cells, as well as increased levels of the host protein HSP70, a protein they found could activate macrophages *in vitro* [184]. Exosomes released from *M.tb*- or *M. bovis* BCG-infected macrophages were also shown to be pro-inflammatory [10]. The mycobacterial 19-kDa lipoprotein present on exosomes that are released from *M. tuberculosis*-infected cells was later shown to be a primary driver of this inflammatory response, which depends on the TLR/MyD88 pathway [185]. Moreover, exosomes isolated from the bronchoalveolar lavage fluid (BALF) of *M. bovis* BCG-infected mice contained mycobacterial components, including the 19-kDa lipoprotein, and were pro-inflammatory *ex vivo*. In addition, exosomes from *M. bovis* BCG- or *M.tb*-infected macrophages could stimulate a pro-inflammatory response *in vivo*, as intranasal injection of mice induced TNF- α and IL-12 production, as well as recruitment of macrophages and neutrophils to the lung [10]. Macrophages treated with exosomes from *M.tb*-infected macrophages secrete chemokines that induce naïve macrophage and T-cell migration *in vitro* [186]. Together, these results suggest that exosomes from mycobacterial-infected cells can promote both recruitment and activation of immune cells *in vitro* and *in vivo* and may play a role in promoting the innate immune response upon a mycobacterial infection. However, the mycobacterial components present on/in exosomes could also function to suppress the immune response. In recent studies, we observed that exosomes from *M.tb*-infected cells could partially suppress the ability of recipient macrophages to respond to IFN- γ , inhibition that was dependent on macrophage expression of TLR2 and MyD88 [187]. Additional studies are needed to define the receptors and signaling responses induced upon exosome–macrophage interaction and how these interactions/responses change as the exosome composition is modified during an infection. In addition to their effect on macrophage activation, exosomes from *M.tb*-infected cells have also been shown to contain a member of the PE family (Rv1818c) that can induce apoptosis in Jurkat T cells [188], suggesting that the inhibitory effect of these exosomes may extend to T cells.

However, exosomes released from *M.tb*- or *M. bovis* BCG-infected cells, or from *M.tb* culture filtrate protein (CFP)-treated macrophages, can also activate antigen-specific CD4⁺ and CD8⁺ T cells *in vivo* and promote the activation and maturation of bone marrow-derived dendritic cells (BMDCs) [189]. These exosomes induce a Th1 immune response, as defined by antigen-specific T-cell production of IFN- γ [187,189]. Moreover, vaccination of mice with exosomes released from macrophages treated with CFP protects mice against a low-dose aerosolized *M.tb* inoculation, equivalent to BCG-vaccinated mice [190]. The release of mycobacterial antigens from infected macrophages is not limited to exosomes. Ramachandra and colleagues observed that infection with *M.tb* or *M. bovis* BCG resulted in increase in both exosome and microvesicle release, and both vesicles could stimulate an antigen-specific T-cell response [191]. Together, these results suggest that exosomes and perhaps other extracellular vesicles are a source of antigen to stimulate the acquired immune response. However, other mechanisms for antigen delivery during a mycobacterial infection have been proposed, including necrotic cells, apoptotic bodies and release of

free antigen [192–194]. Unfortunately, our ability to test the relative importance of exosomes in antigen delivery is limited, due to the lack of molecular tools to block exosome production in macrophages without affecting other aspects of vesicular transport and without blocking exosome production by other cell types.

In addition to mycobacteria, exosomes from *Salmonella*-infected macrophages are also pro-inflammatory, increasing TNF- α production by human monocytes (Fig 4) [10]. These exosomes contain LPS, a known PAMP present on *Salmonella* and other gram-negative bacteria. Exosomes from cells infected with *Mycoplasma* induce a mixed cytokine response, including production of both IFN- γ and IL-10 from B cells. However, these exosomes appear to be primarily inhibitory, at least in the context of T-cell activation [195]. Exosomes can also be carriers of toxins, as shown by Abrami and colleagues, who found lethal factor—a well-characterized toxin produced by *Bacillus anthracis*—packaged into intraluminal vesicles and released on exosomes when expressed in a human epithelial cell line [196]. Ettelaie and colleagues reported that ‘microparticles’ released from *Chlamydia pneumoniae*-infected cells contain TF, a blood coagulation protein, which has also been associated with cell proliferation, migration and apoptosis. The TF-positive microparticles activate NF- κ B, the transcription factor that partially regulates TF expression in endothelial cells. *C. pneumoniae* elementary bodies were also proposed to be released in microparticles, pointing to a potential role in the dissemination of the infection through the bloodstream. These findings have implications not only for the control of the infection by the host, but also for the potential cardiovascular consequences in relation to inflammatory conditions such as atherosclerosis [197]. Although the *C. pneumoniae* vesicles were referred to as microparticles, the isolation procedure used would enrich for exosomes. Several cytotoxic and secreted proteins were also associated with host vesicles released from *Chlamydia trachomatis*, which might function in the delivery of virulence factors [198].

Additional studies have analyzed the presence of bacterial antigens within host exosomes, with an eye toward developing cell-free vaccines against bacterial pathogens. Colino and colleagues treated BMDCs with diphtheria toxin (DT), isolated exosomes from the cells and injected them into mice. The exosomes stimulated an IgG response specific for DT [199]. Similar results were obtained with *Streptococcus pneumoniae*. Exosomes from BMDCs pulsed with *S. pneumoniae* capsular polysaccharide 14 antigen (Cps14) were enriched in Cps14 and could stimulate a protective IgM and IgG response against *S. pneumoniae* when injected into naïve mice [200].

Summary

Together, the results discussed above suggest that microbial and host components can spread beyond the infected cell through exosomes to either activate or suppress immune responses. We hypothesize that exosomes will be involved in multiple steps during the infection process, including formation/modification of infection foci, discrimination of antigens during the initial stages of infection, source of antigens for activation of T cells and B cells and modulation of immune cell function. In addition, the exosomes released from infected cells could also interact with non-immune cells such as fibroblasts and endothelial cells, influencing matrix deposition, vascular permeability, etc., all of which could impact the outcome of an infection (see Sidebar A).

Exosomes: good or bad for the host?

Whether exosomes activate or suppress the immune response depends on multiple factors, as discussed above. One of them is the source of the exosomes, that is, the cell type from which the exosomes were derived and/or the bodily fluid from which they were isolated. For example, exosomes from *Leishmania*-infected DCs were found to be immune stimulatory, making them an effective vaccine against the parasite [159]. In contrast, exosomes from infected macrophages were found to suppress the immune response to the parasite, promoting its survival in the host [155,156]. These different responses stem from changes in exosome composition, including their internal cargo (proteins and RNA) and their surface markers. Differences in the composition of exosomes would, in turn, lead to different effects on the recipient cells. A proteomic analysis of exosomes released from *M.tb*-infected or CFP-treated macrophages identified 41 and 29 mycobacterial proteins present in the exosomes from infected and CFP-treated macrophages, respectively [11]. Many of the proteins identified had been previously characterized as dominant antigens [201,202]. There was also significant overlap between the mycobacterial proteins present in the two populations of exosomes. In contrast, a proteomic analysis of exosomes from *Leishmania*-infected macrophages revealed few parasite proteins and limited differences in host proteins between exosomes from infected compared to uninfected macrophages [156]. One of the few differences was the presence of GP63 on exosomes from infected cells. GP63 is immune modulatory, but not pro-inflammatory, and contributes to parasite survival by down-regulating the immune response of the host. Another example of the significant effect that the presence or absence of a single protein can have on the immune response includes work by Miksa and colleagues in a rat septic model, where exosomes with or without MFG-E8 (milk fat globule epidermal growth factor 8) had a significantly different effect on removal of apoptotic bodies and survival of the rats. MFG-E8-containing exosomes down-regulated the inflammatory response, reducing TNF- α and IL-6 production [203]. In this setting, in which increased immune response to bacteria could be detrimental (by leading to sepsis), the exosomes were able to dampen the immune response due to the presence of MFG-E8 within the vesicles.

Understanding the beneficial or harmful effects of exosomes in the context of an *in vivo* infection is a key goal that will require additional insight into exosome biogenesis, and new tools to specifically block exosome release in a cell-specific manner. At present, targeting Rab GTPases or the various ESCRT proteins does not afford the control and specificity we need to answer these questions. Other factors, such as adaptor proteins that are specific for the tethering and fusion of MVBs with the plasma membrane, would be logical choices. Unfortunately, although SNAREs such as VAMP7 have been implicated in the MVB–plasma membrane fusion [204], this SNARE is also involved in other intracellular membrane fusion processes and therefore not a useful target for blocking exosome biogenesis.

Exosomes as vaccines

The concept of using exosomes as vaccines has its origin in the cancer field. Exosomes released from dendritic cells pulsed with

tumor antigens have been tested in clinical trials as tumor ‘vaccines’: a treatment that aims to mobilize a patient’s immune system to recognize and destroy the tumor cells. More recently, the potential use of exosomes as vaccines against infectious diseases has been assessed. Specific examples have been discussed in the different pathogen sections above. There are a number of potential advantages to using exosomes as vaccines against pathogens. These include: (i) more stable conformational conditions for the proteins; (ii) improved molecular distribution due to the ability of exosomes to circulate in bodily fluids and reach distal organs; (iii) more efficient association with the antigen-presenting cells, due to the expression of adhesion molecules on exosomes; and (iv) the fact that exosomes are one of the body’s ‘natural’ mechanisms for transporting antigens between cells and one that likely plays a role in cross-priming.

However, although the use of exosomes allows for a cell-free-based vaccine, there are both conceptual and practical issues that need to be addressed before this potential application can become a reality. These include obtaining exosomes with the correct mix of antigens that provide protection, being able to reproducibly generate exosomes with this correct antigen composition, the risks of introducing ‘non-self’ human molecules into a vaccinated individual, among other issues. This latter point is particularly important, as unlike the use of exosomes as vaccines in cancer patients—which uses exosomes obtained from autologous cells—a vaccine against a particular pathogen will likely be derived from a human cell line and therefore will have proteins and other molecules specific to this cell line. The effect of these ‘foreign’ antigens on the recipient’s immune response is unknown, and additional experiments will be required before performing any clinical studies. Nevertheless, the available data indicate that exosomes may provide a unique approach to vaccine generation against various pathogens, and this area will likely grow significantly in the coming years.

Exosomes as a source of diagnostic markers

Exosomes have been isolated from many different body fluids, including serum, bronchoalveolar lavage fluid, urine, saliva and several others [205–207]. A number of studies have shown quantitative and qualitative differences in exosome composition between healthy individuals and those with underlying diseases, including cancers and renal diseases [208]. These differences, combined with their easy accessibility, make exosomes excellent biomarker candidates. The use of exosomes to diagnose infectious diseases has been less studied, but shows great promise, as the markers could be both host and pathogen derived. Some support for this idea comes from the fact that serum exosome levels are significantly elevated in *M. bovis* BCG-infected mice compared to uninfected controls, and exosome concentration correlates with bacterial load [186]. Moreover, the exosomes isolated from the bronchoalveolar lavage fluid of *M.tb*-infected mice contain mycobacterial proteins, some of which are present in exosomes throughout a 112-day infection [209]. Finally, we have isolated exosomes from TB patient serum and identified a number of mycobacterial proteins, some of which were consistently found in the patient population under study, suggesting that they could be viable biomarkers for disease [210]. Surprisingly, we have also found that macrophages infected with *M.tb* release

Sidebar A: In need of answers

- (i) Through which mechanism(s) are microbial components transported to MVBs and onto exosomes?
- (ii) Do pathogens modify the MVB/exosome biogenesis pathway to limit the exposure of their components to the extracellular environment? Do they have mechanisms to specifically target certain molecules to MVBs/exosomes?
- (iii) How does the function and composition of exosomes vary with the type or virulence of a pathogen?
- (iv) Do exosomes function as an important mechanism for antigen presentation during an infection? Under which circumstances does this occur?
- (v) Which cells, in addition to those infected, release exosomes during the course of an infection? Do these exosomes affect the immune or inflammatory response?

exosomes containing mycobacterial RNA (J.S. Schorey, unpublished data), which suggests that exosomal RNA may be a useful marker for active TB. Further experiments are warranted to determine whether RNA from other intracellular pathogens is also present in exosomes.

From the perspective of host markers, Welker and colleagues found the exosomal protein CD81 to be elevated in the serum of patients with chronic hepatitis C infection compared to healthy controls. There was a correlation between serum CD81 elevation, higher ALT levels (a measure of liver inflammation) and more severe liver fibrosis. This suggests that measuring CD81 in the exosomal fraction of patient serum could be useful in the diagnosis or in following the course of chronic hepatitis C infection [211]. These examples illustrate the excellent potential for exosomes and other extracellular vesicles in the diagnosis and prognosis of infectious diseases.

Conclusion and future directions

Our understanding of the relevance of exosomes in host–pathogen interactions is still at an early stage relative to other fields of study, particularly cancer, on which most studies on exosomes have focused. Nevertheless, there are interesting and compelling results regarding the importance of exosomes and other extracellular vesicles during infection, and continued growth in this area will allow for a better understanding of virulence mechanisms and immune responses, as well as the development of new diagnostics and vaccines. However, more work is clearly needed on defining exosome composition and function during the course of an infection. This should include defining the cell types that produce the exosomes, the exosome recipient cells, the intracellular signaling pathways affected by exosomes, etc. Critical to this work will be the development of methods to specifically block exosome production and evaluate disease outcome, as a way to determine whether exosome production benefits the host or is used by the pathogen to subvert the immune response.

Acknowledgements

The unpublished studies highlighted in the review were supported through the grant RO1AI052439 from the National Institute of Allergy and Infectious Diseases.

Author contributions

JSS, YC, PPC and VLS all contributed to researching and writing the review paper.

Conflict of interest

The authors declare that they have no conflict of interest.

References

1. Kumar H, Kawai T, Akira S (2011) Pathogen recognition by the innate immune system. *Int Rev Immunol* 30: 16–34
2. Bliska JB, Wang X, Viboud GI, Brodsky IE (2013) Modulation of innate immune responses by *Yersinia* type III secretion system translocators and effectors. *Cell Microbiol* 15: 1622–1631
3. Rana RR, Simpson P, Zhang M, Jennions M, Ukegbu C, Spear AM, Alguet Y, Matthews SJ, Atkins HS, Byrne B (2011) *Yersinia pestis* TIR-domain protein forms dimers that interact with the human adaptor protein MyD88. *Microb Pathog* 51: 89–95
4. Schmolke M, Patel JR, de Castro E, Sánchez-Aparicio MT, Uccellini MB, Miller JC, Manicassamy B, Satoh T, Kawai T, Akira S et al (2014) RIG-I detects mRNA of intracellular *Salmonella enterica* serovar *Typhimurium* during bacterial infection. *MBio* 5: e01006–e01014
5. Yadav M, Roach SK, Schorey JS (2004) Increased mitogen-activated protein kinase activity and TNF- α production associated with *Mycobacterium smegmatis*- but not *Mycobacterium avium*-infected macrophages requires prolonged stimulation of the calmodulin/calmodulin kinase and cyclic AMP/protein kinase A pathways. *J Immunol* 172: 5588–5597
6. Yadav M, Schorey JS (2006) The beta-glucan receptor dectin-1 functions together with TLR2 to mediate macrophage activation by mycobacteria. *Blood* 108: 3168–3175
7. Chikere K, Chou T, Gorry PR, Lee B (2013) Affinofile profiling: how efficiency of CD4/CCR5 usage impacts the biological and pathogenic phenotype of HIV. *Virology* 435: 81–91
8. Pizarro-Cerda J, Cossart P (2006) Subversion of cellular functions by *Listeria monocytogenes*. *J Pathol* 208: 215–223
9. Ashida H, Mimuro H, Ogawa M, Kobayashi T, Sanada T, Kim M, Sasakawa C (2011) Cell death and infection: a double-edged sword for host and pathogen survival. *J Cell Biol* 195: 931–942
10. Bhatnagar S, Shinagawa K, Castellino FJ, Schorey JS (2007) Exosomes released from macrophages infected with intracellular pathogens stimulate a proinflammatory response in vitro and in vivo. *Blood* 110: 3234–3244
11. Giri PK, Kruh NA, Dobos KM, Schorey JS (2010) Proteomic analysis identifies highly antigenic proteins in exosomes from *M. tuberculosis*-infected and culture filtrate protein-treated macrophages. *Proteomics* 10: 3190–3202
12. Winter J, Letley D, Rhead J, Atherton J, Robinson K (2014) *Helicobacter pylori* membrane vesicles stimulate innate pro- and anti-inflammatory responses and induce apoptosis in Jurkat T cells. *Infect Immun* 82: 1372–1381
13. Deatherage BL, Cookson BT (2012) Membrane vesicle release in bacteria, eukaryotes, and archaea: a conserved yet underappreciated aspect of microbial life. *Infect Immun* 80: 1948–1957
14. Kulp A, Kuehn MJ (2010) Biological functions and biogenesis of secreted bacterial outer membrane vesicles. *Annu Rev Microbiol* 64: 163–184

15. Acevedo R, Fernández S, Zayas C, Acosta A, Sarmiento ME, Ferro VA, Rosenqvist E, Campa C, Cardoso D, Garcia L *et al* (2014) Bacterial outer membrane vesicles and vaccine applications. *Front Immunol* 5: 121
16. Silverman JM, Reiner NE (2011) Exosomes and other microvesicles in infection biology: organelles with unanticipated phenotypes. *Cell Microbiol* 13: 1–9
17. Oliveira DL, Rizzo J, Joffe LS, Godinho RM, Rodrigues ML (2013) Where do they come from and where do they go: candidates for regulating extracellular vesicle formation in fungi. *Int J Mol Sci* 14: 9581–9603
18. D'Souza-Schorey C, Clancy JW (2012) Tumor-derived microvesicles: shedding light on novel microenvironment modulators and prospective cancer biomarkers. *Genes Dev* 26: 1287–1299
19. Raposo G, Nijman HW, Stoorvogel W, Liejendekker R, Harding CV, Melief CJ, Geuze HJ (1996) B lymphocytes secrete antigen-presenting vesicles. *J Exp Med* 183: 1161–1172
20. Raposo G, Tenza D, Mecheri S, Peronet R, Bonnerot C, Desaymard C (1997) Accumulation of major histocompatibility complex class II molecules in mast cell secretory granules and their release upon degranulation. *Mol Biol Cell* 8: 2631–2645
21. Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, Ricciardi-Castagnoli P, Raposo G, Amigorena S (1998) Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. *Nat Med* 4: 594–600
22. Thery C, Regnault A, Garin J, Wolfers J, Zitvogel L, Ricciardi-Castagnoli P, Raposo G, Amigorena S (1999) Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73. *J Cell Biol* 147: 599–610
23. Heijnen HF, Schiel AE, Fijnheer R, Geuze HJ, Sixma JJ (1999) Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. *Blood* 94: 3791–3799
24. Marzesco AM, Janich P, Wilsch-Brauninger M, Dubreuil V, Langenfeld K, Corbeil D, Huttner WB (2005) Release of extracellular membrane particles carrying the stem cell marker prominin-1 (CD133) from neural progenitors and other epithelial cells. *J Cell Sci* 118: 2849–2858
25. Fauré J, Lachenal G, Court M, Hirrlinger J, Chatellard-Causse C, Blot B, Grange J, Schoehn G, Goldberg Y, Boyer V *et al* (2006) Exosomes are released by cultured cortical neurones. *Mol Cell Neurosci* 31: 642–648
26. Guescini M, Genedani S, Stocchi V, Agnati LF (2008) Astrocytes and Glioblastoma cells release exosomes carrying mtDNA. *J Neural Transm* 117: 1–4
27. Zhu M, Li Y, Shi J, Feng W, Nie G, Zhao Y (2012) Exosomes as extrapulmonary signaling conveyors for nanoparticle-induced systemic immune activation. *Small* 8: 404–412
28. Johnstone RM, Adam M, Hammond JR, Orr L, Turbide C (1987) Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). *J Biol Chem* 262: 9412–9420
29. Harding C, Heuser J, Stahl P (1984) Endocytosis and intracellular processing of transferrin and colloidal gold-transferrin in rat reticulocytes: demonstration of a pathway for receptor shedding. *Eur J Cell Biol* 35: 256–263
30. Woodman PG, Futter CE (2008) Multivesicular bodies: co-ordinated progression to maturity. *Curr Opin Cell Biol* 20: 408–414
31. Hurley JH (2010) The ESCRT complexes. *Crit Rev Biochem Mol Biol* 45: 463–487
32. Davies BA, Lee JR, Oestreich AJ, Katzmann DJ (2009) Membrane protein targeting to the MVB/lysosome. *Chem Rev* 109: 1575–1586
33. Metcalf D, Isaacs AM (2010) The role of ESCRT proteins in fusion events involving lysosomes, endosomes and autophagosomes. *Biochem Soc Trans* 38: 1469–1473
34. Raiborg C, Stenmark H (2002) Hrs and endocytic sorting of ubiquitinated membrane proteins. *Cell Struct Funct* 27: 403–408
35. Katzmann DJ, Babst M, Emr SD (2001) Ubiquitin-dependent sorting into the multivesicular body pathway requires the function of a conserved endosomal protein sorting complex, ESCRT-I. *Cell* 106: 145–155
36. Babst M, Katzmann DJ, Snyder WB, Wendland B, Emr SD (2002) Endosome-associated complex, ESCRT-II, recruits transport machinery for protein sorting at the multivesicular body. *Dev Cell* 3: 283–289
37. Wollert T, Wunder C, Lippincott-Schwartz J, Hurley JH (2009) Membrane scission by the ESCRT-III complex. *Nature* 458: 172–177
38. Hanson PI, Cashikar A (2012) Multivesicular body morphogenesis. *Annu Rev Cell Dev Biol* 28: 337–362
39. Tamai K, Tanaka N, Nakano T, Kakazu E, Kondo Y, Inoue J, Shiina M, Fukushima K, Hoshino T, Sano K *et al* (2010) Exosome secretion of dendritic cells is regulated by Hrs, an ESCRT-0 protein. *Biochem Biophys Res Commun* 399: 384–390
40. Stuffers S, Sem Wegner C, Stenmark H, Brech A (2009) Multivesicular endosome biogenesis in the absence of ESCRTs. *Traffic* 10: 925–937
41. Trajkovic K, Hsu C, Chiantia S, Rajendran L, Wenzel D, Wieland F, Schwille P, Brugger B, Simons M (2008) Ceramide triggers budding of exosome vesicles into multivesicular endosomes. *Science* 319: 1244–1247
42. van Niel G, Charrin S, Simoes S, Romao M, Rochin L, Saftig P, Marks MS, Rubinstein E, Raposo G (2011) The tetraspanin CD63 regulates ESCRT-independent and -dependent endosomal sorting during melanogenesis. *Dev Cell* 21: 708–721
43. Perez-Hernandez D, Gutierrez-Vazquez C, Jorge I, Lopez-Martin S, Ursa A, Sanchez-Madrid F, Vazquez J, Yanez-Mo M (2013) The intracellular interactome of tetraspanin-enriched microdomains reveals their function as sorting machineries toward exosomes. *J Biol Chem* 288: 11649–11661
44. Buschow SI, Nolte-t Hoen EN, van Niel G, Pols MS, ten Broeke T, Lauwen M, Ossendorp F, Melief CJ, Raposo G, Wubbolts R, Wauben MH *et al* (2009) MHC II in dendritic cells is targeted to lysosomes or T cell-induced exosomes via distinct multivesicular body pathways. *Traffic* 10: 1528–1542
45. Colombo M, Raposo G, Thery C (2014) Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. *Annu Rev Cell Dev Biol* 30: 255–289
46. Schwartz SL, Cao C, Pylypenko O, Rak A, Wandinger-Ness A (2007) Rab GTPases at a glance. *J Cell Sci* 120: 3905–3910
47. Savina A, Vidal M, Colombo MI (2002) The exosome pathway in K562 cells is regulated by Rab11. *J Cell Sci* 115: 2505–2515
48. Hsu C, Morohashi Y, Yoshimura S, Manrique-Hoyos N, Jung S, Lauterbach MA, Bakhti M, Grønberg M, Möbius W, Rhee J *et al* (2010) Regulation of exosome secretion by Rab35 and its GTPase-activating proteins TBC1D10A-C. *J Cell Biol* 189: 223–232
49. Ostrowski M, Carmo NB, Krumeich S, Fanget I, Raposo G, Savina A, Moita CF, Schauer K, Hume AN, Freitas RP *et al* (2011) Rab27a and Rab27b control different steps of the exosome secretion pathway. *Nat Cell Biol* 12: 19–30; sup pp 11–13
50. Sreekumar PG, Kannan R, Kitamura M, Spee C, Barron E, Ryan SJ, Hinton DR (2010) alphaB crystallin is apically secreted within

- exosomes by polarized human retinal pigment epithelium and provides neuroprotection to adjacent cells. *PLoS One* 5: e12578
51. Choi DS, Kim DK, Kim YK, Gho YS (2014) Proteomics of extracellular vesicles: exosomes and ectosomes. *Mass Spectrom Rev* doi: 10.1002/mas.21420
 52. Baietti MF, Zhang Z, Mortier E, Melchior A, Degeest G, Geeraerts A, Ivarsson Y, Depoortere F, Coomans C, Vermeiren E et al (2012) Syndecan-syntenin-ALIX regulates the biogenesis of exosomes. *Nat Cell Biol* 14: 677–685
 53. Subra C, Laulagnier K, Perret B, Record M (2007) Exosome lipidomics unravels lipid sorting at the level of multivesicular bodies. *Biochimie* 89: 205–212
 54. Choi DS, Kim DK, Kim YK, Gho YS (2013) Proteomics, transcriptomics and lipidomics of exosomes and ectosomes. *Proteomics* 13: 1554–1571
 55. Wood SL, Knowles MA, Thompson D, Selby PJ, Banks RE (2013) Proteomic studies of urinary biomarkers for prostate, bladder and kidney cancers. *Nat Rev Urol* 10: 206–218
 56. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO (2007) Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat Cell Biol* 9: 654–659
 57. Nolte-t Hoen EN, Buermans HP, Waasdorp M, Stoorvogel W, Wauben MH, t Hoen PA (2012) Deep sequencing of RNA from immune cell-derived vesicles uncovers the selective incorporation of small non-coding RNA biotypes with potential regulatory functions. *Nucleic Acids Res* 40: 9272–9285
 58. Mittelbrunn M, Gutierrez-Vazquez C, Villarroya-Beltri C, Gonzalez S, Sanchez-Cabo F, Gonzalez MA, Bernad A, Sanchez-Madrid F (2011) Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. *Nat Commun* 2: 282
 59. Montecalvo A, Larregina AT, Shufesky WJ, Stolz DB, Sullivan ML, Karlsson JM, Baty CJ, Gibson GA, Erdos G, Wang Z et al (2012) Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. *Blood* 119: 756–766
 60. Skog J, Würdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, Curry Jr WT, Carter BS, Krichevsky AM, Breakefield XO (2008) Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. *Nat Cell Biol* 10: 1470–1476
 61. Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, Yu L, Xiao T, Schafer J, Lee ML, Schmittgen TD et al (2008) Detection of microRNA expression in human peripheral blood microvesicles. *PLoS One* 3: e3694
 62. Michael A, Bajracharya SD, Yuen PS, Zhou H, Star RA, Illei GG, Alevizos I (2010) Exosomes from human saliva as a source of microRNA biomarkers. *Oral Dis* 16: 34–38
 63. Eldh M, Ekstrom K, Valadi H, Sjostrand M, Olsson B, Jernas M, Lotvall J (2010) Exosomes communicate protective messages during oxidative stress; possible role of exosomal shuttle RNA. *PLoS One* 5: e15353
 64. Lotvall J, Valadi H (2007) Cell to cell signalling via exosomes through esRNA. *Cell Adh Migr* 1: 156–158
 65. Li CC, Eaton SA, Young PE, Lee M, Shuttleworth R, Humphreys DT, Grau GE, Combes V, Bewawy M, Gong J et al (2013) Glioma microvesicles carry selectively packaged coding and non-coding RNAs which alter gene expression in recipient cells. *RNA Biol* 10: 1333–1344
 66. Morita E, Sundquist WI (2004) Retrovirus budding. *Annu Rev Cell Dev Biol* 20: 395–425
 67. Garcia E, Pion M, Pelchen-Matthews A, Collinson L, Arrighi JF, Blot G, Leuba F, Escola JM, Demaurex N, Marsh M et al (2005) HIV-1 trafficking to the dendritic cell-T-cell infectious synapse uses a pathway of tetraspanin sorting to the immunological synapse. *Traffic* 6: 488–501
 68. Lenassi M, Cagney G, Liao M, Vaupotic T, Bartholomeeusen K, Cheng Y, Krogan NJ, Plemenitas A, Peterlin BM (2010) HIV Nef is secreted in exosomes and triggers apoptosis in bystander CD4⁺ T cells. *Traffic* 11: 110–122
 69. Mehra A, Zahra A, Thompson V, Sirisaengtaksin N, Wells A, Porto M, Köster S, Penberthy K, Kubota Y, Dricot A et al (2013) *Mycobacterium tuberculosis* type VII secreted effector EsxH targets host ESCRT to impair trafficking. *PLoS Pathog* 9: e1003734
 70. Dreux M, Garaigorta U, Boyd B, Decembre E, Chung J, Whitten-Bauer C, Wieland S, Chisari FV (2012) Short-range exosomal transfer of viral RNA from infected cells to plasmacytoid dendritic cells triggers innate immunity. *Cell Host Microbe* 12: 558–570
 71. Ghoulaj B, Milev MP, Ajamian L, Abel K, Moulund AJ (2012) ESCRT-II's involvement in HIV-1 genomic RNA trafficking and assembly. *Biol Cell* 104: 706–721
 72. Mathews A, Holland L, Yankulov K (2009) The interaction between EAP30 and ELL is modulated by MCM2. *FEBS Lett* 583: 3431–3436
 73. Irion U, St Johnston D (2007) bicoid RNA localization requires specific binding of an endosomal sorting complex. *Nature* 445: 554–558
 74. Martin KC, Ephrussi A (2009) mRNA localization: gene expression in the spatial dimension. *Cell* 136: 719–730
 75. Bobrie A, Colombo M, Raposo G, Thery C (2011) Exosome secretion: molecular mechanisms and roles in immune responses. *Traffic* 12: 1659–1668
 76. Beninson LA, Fleshner M (2014) Exosomes: an emerging factor in stress-induced immunomodulation. *Semin Immunol* 26: 394–401
 77. Munich S, Sobo-Vujanovic A, Buchser WJ, Beer-Stolz D, Vujanovic NL (2012) Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands. *Oncoimmunology* 1: 1074–1083
 78. Simhadri VR, Reiners KS, Hansen HP, Topolar D, Simhadri VL, Nohroudi K, Kufer TA, Engert A, Pogge von Strandmann E (2008) Dendritic cells release HLA-B-associated transcript-3 positive exosomes to regulate natural killer function. *PLoS One* 3: e3377
 79. Obregon C, Rothen-Rutishauser B, Gerber P, Gehr P, Nicod LP (2009) Active uptake of dendritic cell-derived exovesicles by epithelial cells induces the release of inflammatory mediators through a TNF-alpha-mediated pathway. *Am J Pathol* 175: 696–705
 80. Teo BH, Wong SH (2010) MHC class II-associated invariant chain (Ii) modulates dendritic cells-derived microvesicles (DCMV)-mediated activation of microglia. *Biochem Biophys Res Commun* 400: 673–678
 81. Qu Y, Franchi L, Nunez G, Dubyak GR (2007) Nonclassical IL-1 beta secretion stimulated by P2X7 receptors is dependent on inflammasome activation and correlated with exosome release in murine macrophages. *J Immunol* 179: 1913–1925
 82. Qu Y, Ramachandra L, Mohr S, Franchi L, Harding CV, Nunez G, Dubyak GR (2009) P2X7 receptor-stimulated secretion of MHC class II-containing exosomes requires the ASC/NLRP3 inflammasome but is independent of caspase-1. *J Immunol* 182: 5052–5062
 83. Truman JP, Al Gadban MM, Smith KJ, Jenkins RW, Mayroo N, Virella G, Lopes-Virella MF, Bielawska A, Hannun YA, Hammad SM (2012) Differential regulation of acid sphingomyelinase in macrophages stimulated with oxidized low-density lipoprotein (LDL) and oxidized LDL immune complexes: role in phagocytosis and cytokine release. *Immunology* 136: 30–45
 84. Thery C, Duban L, Segura E, Veron P, Lantz O, Amigorena S (2002) Indirect activation of naive CD4⁺ T cells by dendritic cell-derived exosomes. *Nat Immunol* 3: 1156–1162

85. André F, Chaput N, Scharztz NE, Flament C, Aubert N, Bernard J, Lemonnier F, Raposo G, Escudier B, Hsu DH et al (2004) Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. *J Immunol* 172: 2126–2136
86. Chaput N, Scharztz NE, André F, Taieb J, Novault S, Bonnaventure P, Aubert N, Bernard J, Lemonnier F, Merad M et al (2004) Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. *J Immunol* 172: 2137–2146
87. Segura E, Amigorena S, Thery C (2005) Mature dendritic cells secrete exosomes with strong ability to induce antigen-specific effector immune responses. *Blood Cells Mol Dis* 35: 89–93
88. Montecalvo A, Shufesky WJ, Stolz DB, Sullivan MG, Wang Z, Divito SJ, Papworth GD, Watkins SC, Robbins PD, Larregina AT et al (2008) Exosomes as a short-range mechanism to spread alloantigen between dendritic cells during T cell allorecognition. *J Immunol* 180: 3081–3090
89. Qazi KR, Gehrman U, Domange Jordo E, Karlsson MC, Gabrielsson S (2009) Antigen-loaded exosomes alone induce Th1-type memory through a B-cell-dependent mechanism. *Blood* 113: 2673–2683
90. Veron P, Segura E, Sugano G, Amigorena S, Thery C (2005) Accumulation of MFG-E8/lactadherin on exosomes from immature dendritic cells. *Blood Cells Mol Dis* 35: 81–88
91. Segura E, Nicco C, Lombard B, Veron P, Raposo G, Batteux F, Amigorena S, Thery C (2005) ICAM-1 on exosomes from mature dendritic cells is critical for efficient naive T-cell priming. *Blood* 106: 216–223
92. Zakharova L, Svetlova M, Fomina AF (2007) T cell exosomes induce cholesterol accumulation in human monocytes via phosphatidylserine receptor. *J Cell Physiol* 112: 174–181
93. Miyanishi M, Tada K, Koike M, Uchiyama Y, Kitamura T, Nagata S (2007) Identification of Tim4 as a phosphatidylserine receptor. *Nature* 450: 435–439
94. Hao S, Bai O, Li F, Yuan J, Laferte S, Xiang J (2007) Mature dendritic cells pulsed with exosomes stimulate efficient cytotoxic T-lymphocyte responses and antitumor immunity. *Immunology* 120: 90–102
95. Nolte-t Hoen EN, Buschow SI, Anderton SM, Stoorvogel W, Wauben MH (2009) Activated T cells recruit exosomes secreted by dendritic cells via LFA-1. *Blood* 113: 1977–1981
96. Utsugi-Kobukai S, Fujimaki H, Hotta C, Nakazawa M, Minami M (2003) MHC class I-mediated exogenous antigen presentation by exosomes secreted from immature and mature bone marrow derived dendritic cells. *Immunol Lett* 89: 125–131
97. Admyre C, Johansson SM, Paulie S, Gabrielsson S (2006) Direct exosome stimulation of peripheral human T cells detected by ELISPOT. *Eur J Immunol* 36: 1772–1781
98. Luketic L, Delanghe J, Sobol PT, Yang P, Frotten E, Mossman KL, Gaudie J, Bramson J, Wan Y (2007) Antigen presentation by exosomes released from peptide-pulsed dendritic cells is not suppressed by the presence of active CTL. *J Immunol* 179: 5024–5032
99. Muntasell A, Berger AC, Roche PA (2007) T cell-induced secretion of MHC class II-peptide complexes on B cell exosomes. *EMBO J* 26: 4263–4272
100. Admyre C, Bohle B, Johansson SM, Focke-Tejkl M, Valenta R, Scheynius A, Gabrielsson S (2007) B cell-derived exosomes can present allergen peptides and activate allergen-specific T cells to proliferate and produce TH2-like cytokines. *J Allergy Clin Immunol* 120: 1418–1424
101. Hwang I, Shen X, Sprent J (2003) Direct stimulation of naive T cells by membrane vesicles from antigen-presenting cells: distinct roles for CD54 and B7 molecules. *Proc Natl Acad Sci USA* 100: 6670–6675
102. Vincent-Schneider H, Stumptner-Cuvelette P, Lankar D, Pain S, Raposo G, Benaroch P, Bonnerot C (2002) Exosomes bearing HLA-DR1 molecules need dendritic cells to efficiently stimulate specific T cells. *Int Immunol* 14: 713–722
103. Yin W, Ouyang S, Li Y, Xiao B, Yang H (2013) Immature dendritic cell-derived exosomes: a promise subcellular vaccine for autoimmunity. *Inflammation* 36: 232–240
104. Yang C, Robbins PD (2012) Immunosuppressive exosomes: a new approach for treating arthritis. *Int J Rheumatol* 2012: 573528
105. Blanchard N, Lankar D, Faure F, Regnault A, Dumont C, Raposo G, Hivroz C (2002) TCR activation of human T cells induces the production of exosomes bearing the TCR/CD3/zeta complex. *J Immunol* 168: 3235–3241
106. Wahlgren J, Karlson Tde L, Glader P, Telemo E, Valadi H (2012) Activated human T cells secrete exosomes that participate in IL-2 mediated immune response signaling. *PLoS One* 7: e49723
107. Smyth LA, Ratnasothy K, Tsang JY, Boardman D, Warley A, Lechler R, Lombardi G (2013) CD73 expression on extracellular vesicles derived from CD4⁺ CD25⁺ Foxp3⁺ T cells contributes to their regulatory function. *Eur J Immunol* 43: 2430–2440
108. Zhang H, Xie Y, Li W, Chibbar R, Xiong S, Xiang J (2011) CD4(+) T cell-released exosomes inhibit CD8(+) cytotoxic T-lymphocyte responses and antitumor immunity. *Cell Mol Immunol* 8: 23–30
109. Xie Y, Zhang X, Zhao T, Li W, Xiang J (2013) Natural CD8(+)25(+) regulatory T cell-secreted exosomes capable of suppressing cytotoxic T lymphocyte-mediated immunity against B16 melanoma. *Biochem Biophys Res Commun* 438: 152–155
110. Alonso R, Mazzeo C, Merida I, Izquierdo M (2007) A new role of diacylglycerol kinase alpha on the secretion of lethal exosomes bearing Fas ligand during activation-induced cell death of T lymphocytes. *Biochimie* 89: 213–221
111. Cai Z, Yang F, Yu L, Yu Z, Jiang L, Wang Q, Yang Y, Wang L, Cao X, Wang J (2012) Activated T cell exosomes promote tumor invasion via Fas signaling pathway. *J Immunol* 188: 5954–5961
112. Klinker MW, Lizzio V, Reed TJ, Fox DA, Lundy SK (2014) Human B cell-derived lymphoblastoid cell lines constitutively produce Fas ligand and secrete MHCII(+)FasL(+) killer exosomes. *Front Immunol* 5: 144
113. Morita E (2012) Differential requirements of mammalian ESCRTs in multivesicular body formation, virus budding and cell division. *FEBS J* 279: 1399–1406
114. Wurdinger T, Gatzon NN, Balaj L, Kaur B, Breakefield XO, Pegtel DM (2012) Extracellular vesicles and their convergence with viral pathways. *Adv Virol* 2012: 767694
115. Cashikar AG, Shim S, Roth R, Maldazys MR, Heuser JE, Hanson PI (2014) Structure of cellular ESCRT-III spirals and their relationship to HIV budding. *Elife* 3: e02184
116. Baumgartel V, Ivanchenko S, Dupont A, Sergeev M, Wiseman PW, Krausslich HG, Brauchle C, Muller B, Lamb DC (2011) Live-cell visualization of dynamics of HIV budding site interactions with an ESCRT component. *Nat Cell Biol* 13: 469–474
117. Mack M, Kleinschmidt A, Brühl H, Klier C, Nelson PJ, Cihak J, Plachý J, Stangassinger M, Erfle V, Schlöndorff D (2000) Transfer of the chemokine receptor CCR5 between cells by membrane-derived microparticles: a

- mechanism for cellular human immunodeficiency virus 1 infection. *Nat Med* 6: 769–775
118. Rozmyslowicz T, Majka M, Kijowski J, Murphy SL, Conover DO, Poncz M, Ratajczak J, Gaulton GN, Ratajczak MZ (2003) Platelet- and megakaryocyte-derived microparticles transfer CXCR4 receptor to CXCR4-null cells and make them susceptible to infection by X4-HIV. *AIDS* 17: 33–42
 119. Fang Y, Wu N, Gan X, Yan W, Morrell JC, Gould SJ (2007) Higher-order oligomerization targets plasma membrane proteins and HIV gag to exosomes. *PLoS Biol* 5: e158
 120. Narayanan A, Iordanskiy S, Das R, Van Duyne R, Santos S, Jaworski E, Guendel I, Sampey G, Dalby E, Iglesias-Ussel M et al (2013) Exosomes derived from HIV-1-infected cells contain trans-activation response element RNA. *J Biol Chem* 288: 20014–20033
 121. Campbell TD, Khan M, Huang MB, Bond VC, Powell MD (2008) HIV-1 Nef protein is secreted into vesicles that can fuse with target cells and virions. *Ethn Dis* 18: S2–14–19
 122. Shelton MN, Huang MB, Ali SA, Powell MD, Bond VC (2012) Secretion modification region-derived peptide disrupts HIV-1 Nef's interaction with mortalin and blocks virus and Nef exosome release. *J Virol* 86: 406–419
 123. Wang T, Green LA, Gupta SK, Kim C, Wang L, Almodovar S, Flores SC, Prudovsky IA, Jolicoeur P, Liu Z et al (2014) Transfer of intracellular HIV Nef to endothelium causes endothelial dysfunction. *PLoS One* 9: e91063
 124. Aqil M, Naqvi AR, Bano AS, Jameel S (2013) The HIV-1 Nef protein binds argonaute-2 and functions as a viral suppressor of RNA interference. *PLoS One* 8: e74472
 125. Tumne A, Prasad VS, Chen Y, Stolz DB, Saha K, Ratner DM, Ding M, Watkins SC, Gupta P (2009) Noncytotoxic suppression of human immunodeficiency virus type 1 transcription by exosomes secreted from CD8⁺ T cells. *J Virol* 83: 4354–4364
 126. Khatua AK, Taylor HE, Hildreth JE, Popik W (2009) Exosomes packaging APOBEC3G confer human immunodeficiency virus resistance to recipient cells. *J Virol* 83: 512–521
 127. Meckes DG Jr, Gunawardena HP, Dekroon RM, Heaton PR, Edwards RH, Ozgur S, Griffith JD, Damania B, Raab-Traub N (2013) Modulation of B-cell exosome proteins by gamma herpesvirus infection. *Proc Natl Acad Sci USA* 110: E2925–E2933
 128. Chugh PE, Sin SH, Ozgur S, Henry DH, Menezes P, Griffith J, Eron JJ, Damania B, Dittmer DP (2013) Systemically circulating viral and tumor-derived microRNAs in KSHV-associated malignancies. *PLoS Pathog* 9: e1003484
 129. Dukers DF, Meij P, Vervoort MB, Vos W, Scheper RJ, Meijer CJ, Bloemena E, Middeldorp JM (2000) Direct immunosuppressive effects of EBV-encoded latent membrane protein 1. *J Immunol* 165: 663–670
 130. Ikeda M, Longnecker R (2007) Cholesterol is critical for Epstein-Barr virus latent membrane protein 2A trafficking and protein stability. *Virology* 360: 461–468
 131. Klibi J, Niki T, Riedel A, Pioche-Durieu C, Souquere S, Rubinstein E, Le Moulec S, Guigay J, Hirashima M, Guemira F et al (2009) Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells. *Blood* 113: 1957–1966
 132. Ariza ME, Rivallier P, Glaser R, Chen M, Williams MV (2013) Epstein-Barr virus encoded dUTPase containing exosomes modulate innate and adaptive immune responses in human dendritic cells and peripheral blood mononuclear cells. *PLoS One* 8: e69827
 133. Yang HJ, Huang TJ, Yang CF, Peng LX, Liu RY, Yang GD, Chu QQ, Huang JL, Liu N, Huang HB et al (2013) Comprehensive profiling of Epstein-Barr virus-encoded miRNA species associated with specific latency types in tumor cells. *Viral J* 10: 314
 134. Pfeffer S, Zavolan M, Grässer FA, Chien M, Russo JJ, Ju J, John B, Enright AJ, Marks D, Sander C et al (2004) Identification of virus-encoded microRNAs. *Science* 304: 734–736
 135. Pegtel DM, Cosmopoulos K, Thorley-Lawson DA, van Eijndhoven MA, Hopmans ES, Lindenberg JL, de Gruijl TD, Wurdinger T, Middeldorp JM (2010) Functional delivery of viral miRNAs via exosomes. *Proc Natl Acad Sci USA* 107: 6328–6333
 136. Haneklaus M, Gerlic M, Kurowska-Stolarska M, Rainey AA, Pich D, McInnes IB, Hammerschmidt W, O'Neill LA, Masters SL (2012) Cutting edge: miR-223 and EBV miR-BART15 regulate the NLRP3 inflammasome and IL-1beta production. *J Immunol* 189: 3795–3799
 137. Walker JD, Maier CL, Pober JS (2009) Cytomegalovirus-infected human endothelial cells can stimulate allogeneic CD4⁺ memory T cells by releasing antigenic exosomes. *J Immunol* 182: 1548–1559
 138. Plazolles N, Humbert JM, Vachot L, Verrier B, Hocke C, Halary F (2011) Pivotal advance: the promotion of soluble DC-SIGN release by inflammatory signals and its enhancement of cytomegalovirus-mediated cis-infection of myeloid dendritic cells. *J Leukoc Biol* 89: 329–342
 139. Masciopinto F, Giovani C, Campagnoli S, Galli-Stampino L, Colombatto P, Brunetto M, Yen TS, Houghton M, Pileri P, Abrignani S (2004) Association of hepatitis C virus envelope proteins with exosomes. *Eur J Immunol* 34: 2834–2842
 140. Gastaminza P, Dryden KA, Boyd B, Wood MR, Law M, Yeager M, Chisari FV (2010) Ultrastructural and biophysical characterization of hepatitis C virus particles produced in cell culture. *J Virol* 84: 10999–11009
 141. Ramakrishnaiah V, Thumann C, Fofana I, Habersetzer F, Pan Q, de Ruiter PE, Willemsen R, Demmers JA, Stalin Raj V, Jenster G et al (2013) Exosome-mediated transmission of hepatitis C virus between human hepatoma Huh7.5 cells. *Proc Natl Acad Sci USA* 110: 13109–13113
 142. Cosset FL, Dreux M (2014) HCV transmission by hepatic exosomes establishes a productive infection. *J Hepatol* 60: 674–675
 143. Li J, Liu K, Liu Y, Xu Y, Zhang F, Yang H, Liu J, Pan T, Chen J, Wu M et al (2013) Exosomes mediate the cell-to-cell transmission of IFN-alpha-induced antiviral activity. *Nat Immunol* 14: 793–803
 144. Temme S, Eis-Hubinger AM, McLellan AD, Koch N (2010) The herpes simplex virus-1 encoded glycoprotein B diverts HLA-DR into the exosome pathway. *J Immunol* 184: 236–243
 145. Dargan DJ, Patel AH, Subak-Sharpe JH (1995) PREPs: herpes simplex virus type 1-specific particles produced by infected cells when viral DNA replication is blocked. *J Virol* 69: 4924–4932
 146. Yeh PC, Han J, Chadha P, Meckes DG Jr, Ward MD, Semmes OJ, Wills JW (2011) Direct and specific binding of the UL16 tegument protein of herpes simplex virus to the cytoplasmic tail of glycoprotein E. *J Virol* 85: 9425–9436
 147. Robinson SM, Tsueng G, Sin J, Mangale V, Rahawi S, McIntyre LL, Williams W, Kha N, Cruz C, Hancock BM et al (2014) Cocksackievirus B exits the host cell in shed microvesicles displaying autophagosomal markers. *PLoS Pathog* 10: e1004045
 148. Wakim LM, Bevan MJ (2011) Cross-dressed dendritic cells drive memory CD8⁺ T-cell activation after viral infection. *Nature* 471: 629–632
 149. Aline F, Bout D, Amigorena S, Roingard P, Dimier-Poisson I (2004) *Toxoplasma gondii* antigen-pulsed-dendritic cell-derived exosomes

- induce a protective immune response against *T. gondii* infection. *Infect Immun* 72: 4127–4137
150. Beauvillain C, Ruiz S, Guiton R, Bout D, Dimier-Poisson I (2007) A vaccine based on exosomes secreted by a dendritic cell line confers protection against *T. gondii* infection in syngeneic and allogeneic mice. *Microbes Infect* 9: 1614–1622
 151. Beauvillain C, Juste MO, Dion S, Pierre J, Dimier-Poisson I (2009) Exosomes are an effective vaccine against congenital toxoplasmosis in mice. *Vaccine* 27: 1750–1757
 152. Mordue DG, Sibley LD (1997) Intracellular fate of vacuoles containing *Toxoplasma gondii* is determined at the time of formation and depends on the mechanism of entry. *J Immunol* 159: 4452–4459
 153. Coppens I, Dunn JD, Romano JD, Pypaert M, Zhang H, Boothroyd JC, Joiner KA (2006) *Toxoplasma gondii* sequesters lysosomes from mammalian hosts in the vacuolar space. *Cell* 125: 261–274
 154. Silverman JM, Clos J, deOliveira CC, Shirvani O, Fang Y, Wang C, Foster LJ, Reiner NE (2010) An exosome-based secretion pathway is responsible for protein export from *Leishmania* and communication with macrophages. *J Cell Sci* 123: 842–852
 155. Silverman JM, Clos J, Horakova E, Wang AY, Wiesgigl M, Kelly I, Lynn MA, McMaster WR, Foster LJ, Levings MK et al (2010) *Leishmania* exosomes modulate innate and adaptive immune responses through effects on monocytes and dendritic cells. *J Immunol* 185: 5011–5022
 156. Hassani K, Olivier M (2013) Immunomodulatory impact of *Leishmania*-induced macrophage exosomes: a comparative proteomic and functional analysis. *PLoS Negl Trop Dis* 7: e2185
 157. Hassani K, Shio MT, Martel C, Faubert D, Olivier M (2014) Absence of metalloprotease GP63 alters the protein content of *Leishmania* exosomes. *PLoS One* 9: e95007
 158. Ghosh J, Bose M, Roy S, Bhattacharyya SN (2013) *Leishmania donovani* targets Dicer1 to downregulate miR-122, lower serum cholesterol, and facilitate murine liver infection. *Cell Host Microbe* 13: 277–288
 159. Schnitzer JK, Berzel S, Fajardo-Moser M, Remer KA, Moll H (2010) Fragments of antigen-loaded dendritic cells (DC) and DC-derived exosomes induce protective immunity against *Leishmania major*. *Vaccine* 28: 5785–5793
 160. Martin-Jaular L, Nakayasu ES, Ferrer M, Almeida IC, Del Portillo HA (2011) Exosomes from *Plasmodium yoelii*-infected reticulocytes protect mice from lethal infections. *PLoS One* 6: e26588
 161. Campos FM, Franklin BS, Teixeira-Carvalho A, Filho AL, de Paula SC, Fontes CJ, Brito CF, Carvalho LH (2010) Augmented plasma microparticles during acute *Plasmodium vivax* infection. *Malar J* 9: 327
 162. Mantel PY, Hoang AN, Goldowitz I, Potashnikova D, Hamza B, Vorobjev I, Chiran I, Toner M, Irimia D, Ivanov AR et al (2013) Malaria-infected erythrocyte-derived microvesicles mediate cellular communication within the parasite population and with the host immune system. *Cell Host Microbe* 13: 521–534
 163. Regev-Rudzki N, Wilson DW, Carvalho TG, Sisquella X, Coleman BM, Rug M, Bursac D, Angrisano F, Gee M, Hill AF et al (2013) Cell-cell communication between malaria-infected red blood cells via exosome-like vesicles. *Cell* 153: 1120–1133
 164. Couper KN, Barnes T, Hafalla JC, Combes V, Ryffel B, Secher T, Grau GE, Riley EM, de Souza JB (2010) Parasite-derived plasma microparticles contribute significantly to malaria infection-induced inflammation through potent macrophage stimulation. *PLoS Pathog* 6: e1000744
 165. Cestari I, Ansa-Addo E, Deolindo P, Inal JM, Ramirez MI (2012) Trypanosoma cruzi immune evasion mediated by host cell-derived microvesicles. *J Immunol* 188: 1942–1952
 166. Mantel PY, Marti M (2014) The role of extracellular vesicles in *Plasmodium* and other protozoan parasites. *Cell Microbiol* 16: 344–354
 167. Barteneva NS, Maltsev N, Vorobjev IA (2013) Microvesicles and intercellular communication in the context of parasitism. *Front Cell Infect Microbiol* 3: 49
 168. Del Cacho E, Gallego M, Lee SH, Lillehoj HS, Quilez J, Lillehoj EP, Sanchez-Acedo C (2011) Induction of protective immunity against *Eimeria tenella* infection using antigen-loaded dendritic cells (DC) and DC-derived exosomes. *Vaccine* 29: 3818–3825
 169. Hu G, Gong AY, Roth AL, Huang BQ, Ward HD, Zhu G, Larusso NF, Hanson ND, Chen XM (2013) Release of luminal exosomes contributes to TLR4-mediated epithelial antimicrobial defense. *PLoS Pathog* 9: e1003261
 170. Rodrigues ML, Nakayasu ES, Oliveira DL, Nimrichter L, Nosanchuk JD, Almeida IC, Casadevall A (2008) Extracellular vesicles produced by *Cryptococcus neoformans* contain protein components associated with virulence. *Eukaryot Cell* 7: 58–67
 171. Eisenman HC, Frases S, Nicola AM, Rodrigues ML, Casadevall A (2009) Vesicle-associated melanization in *Cryptococcus neoformans*. *Microbiology* 155: 3860–3867
 172. Oliveira DL, Freire-de-Lima CG, Nosanchuk JD, Casadevall A, Rodrigues ML, Nimrichter L (2010) Extracellular vesicles from *Cryptococcus neoformans* modulate macrophage functions. *Infect Immun* 78: 1601–1609
 173. Nicola AM, Frases S, Casadevall A (2009) Lipophilic dye staining of *Cryptococcus neoformans* extracellular vesicles and capsule. *Eukaryot Cell* 8: 1373–1380
 174. Panepinto J, Komperda K, Frases S, Park YD, Djordjevic JT, Casadevall A, Williamson PR (2009) Sec6-dependent sorting of fungal extracellular exosomes and laccase of *Cryptococcus neoformans*. *Mol Microbiol* 71: 1165–1176
 175. Liu D, Wei L, Guo T, Tan W (2014) Detection of DOPA-melanin in the dimorphic fungal pathogen *Penicillium marneffei* and its effect on macrophage phagocytosis in vitro. *PLoS One* 9: e92610
 176. Gehrmann U, Qazi KR, Johansson C, Hulthenby K, Karlsson M, Lundeborg L, Gabrielsson S, Scheynius A (2011) Nanovesicles from *Malassezia sympodialis* and host exosomes induce cytokine responses—novel mechanisms for host-microbe interactions in atopic eczema. *PLoS One* 6: e21480
 177. Vallejo MC, Matsuo AL, Ganiko L, Medeiros LC, Miranda K, Silva LS, Freymüller-Haapalainen E, Sinigaglia-Coimbra R, Almeida IC, Puccia R (2011) The pathogenic fungus *Paracoccidioides brasiliensis* exports extracellular vesicles containing highly immunogenic alpha-Galactosyl epitopes. *Eukaryot Cell* 10: 343–351
 178. Vallejo MC, Nakayasu ES, Longo LV, Ganiko L, Lopes FG, Matsuo AL, Almeida IC, Puccia R (2012) Lipidomic analysis of extracellular vesicles from the pathogenic phase of *Paracoccidioides brasiliensis*. *PLoS One* 7: e39463
 179. Vallejo MC, Nakayasu ES, Matsuo AL, Sobreira TJ, Longo LV, Ganiko L, Almeida IC, Puccia R (2012) Vesicle and vesicle-free extracellular proteome of *Paracoccidioides brasiliensis*: comparative analysis with other pathogenic fungi. *J Proteome Res* 11: 1676–1685
 180. Beatty WL, Russell DG (2000) Identification of mycobacterial surface proteins released into subcellular compartments of infected macrophages. *Infect Immun* 68: 6997–7002
 181. Beatty WL, Ullrich HJ, Russell DG (2001) Mycobacterial surface moieties are released from infected macrophages by a constitutive exocytic event. *Eur J Cell Biol* 80: 31–40

182. Bhatnagar S, Schorey JS (2007) Exosomes released from infected macrophages contain *Mycobacterium avium* glycopeptidolipids and are proinflammatory. *J Biol Chem* 282: 25779–25789
183. Wang JJ, Chen C, Xie PF, Pan Y, Tan YH, Tang LJ (2014) Proteomic analysis and immune properties of exosomes released by macrophages infected with *Mycobacterium avium*. *Microbes Infect* 16: 283–291
184. Anand PK, Anand E, Bleck CK, Anes E, Griffiths G (2010) Exosomal Hsp70 induces a pro-inflammatory response to foreign particles including mycobacteria. *PLoS One* 5: e10136
185. Schorey JS, Bhatnagar S (2008) Exosome function: from tumor immunology to pathogen biology. *Traffic* 9: 871–881
186. Singh PP, Smith VL, Karakousis PC, Schorey JS (2012) Exosomes isolated from mycobacteria-infected mice or cultured macrophages can recruit and activate immune cells in vitro and in vivo. *J Immunol* 189: 777–785
187. Singh PP, LeMaire C, Tan JC, Zeng E, Schorey JS (2011) Exosomes released from *M. tuberculosis* infected cells can suppress IFN-gamma mediated activation of naive macrophages. *PLoS One* 6: e18564
188. Balaji KN, Goyal G, Narayana Y, Srinivas M, Chaturvedi R, Mohammad S (2007) Apoptosis triggered by Rv1818c, a PE family gene from *Mycobacterium tuberculosis* is regulated by mitochondrial intermediates in T cells. *Microbes Infect* 9: 271–281
189. Giri PK, Schorey JS (2008) Exosomes derived from *M. Bovis* BCG infected macrophages activate antigen-specific CD4⁺ and CD8⁺ T cells in vitro and in vivo. *PLoS One* 3: e2461
190. Cheng Y, Schorey JS (2013) Exosomes carrying mycobacterial antigens can protect mice against *Mycobacterium tuberculosis* infection. *Eur J Immunol* 43: 3279–3290
191. Ramachandra L, Qu Y, Wang Y, Lewis CJ, Cobb BA, Takatsu K, Boom WH, Dubyak GR, Harding CV (2010) *Mycobacterium tuberculosis* synergizes with ATP to induce release of microvesicles and exosomes containing major histocompatibility complex class II molecules capable of antigen presentation. *Infect Immun* 78: 5116–5125
192. Behar SM, Martin CJ, Nunes-Alves C, Divangahi M, Remold HG (2011) Lipids, apoptosis, and cross-presentation: links in the chain of host defense against *Mycobacterium tuberculosis*. *Microbes Infect* 13: 749–756
193. Sridharan H, Upton JW (2014) Programmed necrosis in microbial pathogenesis. *Trends Microbiol* 22: 199–207
194. Srivastava S, Ernst JD (2014) Cell-to-cell transfer of *M. tuberculosis* antigens optimizes CD4 T cell priming. *Cell Host Microbe* 15: 741–752
195. Yang C, Chalasani G, Ng YH, Robbins PD (2012) Exosomes released from *Mycoplasma* infected tumor cells activate inhibitory B cells. *PLoS One* 7: e36138
196. Abrami L, Brandi L, Moayeri M, Brown MJ, Krantz BA, Leppla SH, van der Goot FG (2013) Hijacking multivesicular bodies enables long-term and exosome-mediated long-distance action of anthrax toxin. *Cell Rep* 5: 986–996
197. Ettelaie C, Collier ME, James NJ, Li C (2007) Induction of tissue factor expression and release as microparticles in ECV304 cell line by *Chlamydia pneumoniae* infection. *Atherosclerosis* 190: 343–351
198. Frohlich K, Hua Z, Wang J, Shen L (2012) Isolation of *Chlamydia trachomatis* and membrane vesicles derived from host and bacteria. *J Microbiol Methods* 91: 222–230
199. Colino J, Snapper CM (2006) Exosomes from bone marrow dendritic cells pulsed with diphtheria toxoid preferentially induce type 1 antigen-specific IgG responses in naive recipients in the absence of free antigen. *J Immunol* 177: 3757–3762
200. Colino J, Snapper CM (2007) Dendritic cell-derived exosomes express a *Streptococcus pneumoniae* capsular polysaccharide type 14 cross-reactive antigen that induces protective immunoglobulin responses against pneumococcal infection in mice. *Infect Immun* 75: 220–230
201. Bassey EO, Life PF, Catty D, Gaston JS, Kumararatne DS (1996) T-cell response to mycobacterial proteins: a comparative study of tuberculous and control immunoblots of *Mycobacterium tuberculosis* and *M. bovis* BCG. *Tuber Lung Dis* 77: 146–153
202. Demissie A, Ravn P, Olobo J, Doherty TM, Eguale T, Geletu M, Hailu W, Andersen P, Britton S (1999) T-cell recognition of *Mycobacterium tuberculosis* culture filtrate fractions in tuberculosis patients and their household contacts. *Infect Immun* 67: 5967–5971
203. Miksa M, Wu R, Dong W, Das P, Yang D, Wang P (2006) Dendritic cell-derived exosomes containing milk fat globule epidermal growth factor-factor VIII attenuate proinflammatory responses in sepsis. *Shock* 25: 586–593
204. Fader CM, Sanchez DG, Mestre MB, Colombo MI (2009) TI-VAMP/VAMP7 and VAMP3/cellubrevin: two v-SNARE proteins involved in specific steps of the autophagy/multivesicular body pathways. *Biochim Biophys Acta* 1793: 1901–1916
205. Caby MP, Lankar D, Vincendeau-Scherrer C, Raposo G, Bonnerot C (2005) Exosomal-like vesicles are present in human blood plasma. *Int Immunol* 17: 879–887
206. Admyre C, Grunewald J, Thyberg J, Gripenback S, Tornling G, Eklund A, Scheynius A, Gabrielsson S (2003) Exosomes with major histocompatibility complex class II and co-stimulatory molecules are present in human BAL fluid. *Eur Respir J* 22: 578–583
207. Pisitkun T, Shen RF, Knepper MA (2004) Identification and proteomic profiling of exosomes in human urine. *Proc Natl Acad Sci USA* 101: 13368–13373
208. Chaput N, Thery C (2011) Exosomes: immune properties and potential clinical implementations. *Semin Immunopathol* 33: 419–440
209. Dobos K, Schorey JS, Kruh-Garcia N (2011) *Tuberculosis Biomarkers: Prospects from the Bench to the Clinic*. Rijeka, Croatia: InTech – Open Access Publisher
210. Kruh-Garcia NA, Wolfe WL, Chaisson LH, Worodria WO, Nahid P, Schorey JS, Davis JL, Dobos KM (2014) Use of multiple reaction monitoring mass spectrometry to enhance discovery of tuberculosis biomarkers in exosomes. *PLoS One* 9: e103811
211. Welker MW, Reichert D, Susser S, Sarrazin C, Martinez Y, Herrmann E, Zeuzem S, Piiper A, Kronenberger B (2012) Soluble serum CD81 is elevated in patients with chronic hepatitis C and correlates with alanine aminotransferase serum activity. *PLoS One* 7: e30796